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ABSTRACT 
Nestled in the research field exploring the protective mechanisms of whole 
grains against cardiovascular disease (CVD), this thesis focuses on two novel 
candidate biomarkers for whole-grain rye/wheat intake and the effect of rye 
bread intake on plasma low-density lipoproteins (LDLs). A special emphasis 
is on alkylresorcinols, which are rye- and wheat bran-associated 
phytochemicals. Alkylresorcinols are absorbed in humans, and their plasma 
concentration is suggested to serve as a biomarker for whole-grain rye/wheat 
intake. Following absorption, alkylresorcinols are metabolized in the liver to 
3-(3,5-dihydroxyphenyl)-1-propanoic acid (DHPPA) and 3,5-dihydroxy-
benzoic acid (DHBA), which have been identified in plasma and urine. 
Here, we have determined the kinetic parameters for DHPPA and DHBA 
in plasma and urine from 15 humans after ingesting a single serving of rye 
bread (6 slices, 198 g). We showed that DHPPA and DHBA possess good 
biomarker properties with longer half-lives (t1/2) than intact alkylresorcinols. 
This can result in higher fasting plasma concentrations than those for 
alkylresorcinols, which is advantageous when blood samples from low-to-
moderate whole-grain rye consumers are being analyzed. 
Alkylresorcinols possess antioxidant activity in in vitro assays, although 
human data are lacking. Because LDL particles serve as carriers of 
alkylresorcinols in human circulation, and oxidative modification of LDL has 
been linked to atherogenesis, we aimed to study the potential of 
alkylresorcinols to protect LDL particles against oxidation. We also 
determined the efficacy of added plant sterols (PSs) in rye bread to lower 
LDL cholesterol (LDL-C), a known risk factor for CVD. 
We explored with a dietary intervention the effects of rye bread intake on 
plasma LDL by varying the rye bread dose from 0 g/d (baseline) to 99 g/d, 
and finally to 198 g/d. Rye bread was consumed without (n=31, controls) or 
with added PSs (n=32). Intake of 198 g/d of rye bread significantly (P < 
0.001) increased oxidation resistance and alkylresorcinol contents of LDL 
from baseline. However, alkylresorcinol concentration did not correlate with 
the oxidation resistance of LDL. Therefore, alkylresorcinols are presumably 
not the major causative antioxidants in LDL, and their role remains unclear. 
Compared with controls, the PS group exhibited similar improvements in the 
oxidation resistance of LDL, but showed a significant decrease in LDL-C and 
some other lipid risk factors, suggesting that PS enrichment further 
increased the health benefits of whole-grain rye.  
In summary, this thesis characterizes the kinetics of DHPPA and DHBA 
and supports their suitability as biomarkers for whole-grain rye intake. 
Moreover, rye bread intake was shown to significantly increase in vitro 
oxidation resistance of LDL, and, when enriched with PSs, to also lower 
plasma LDL-C, providing a promising dietary means for prevention of CVD.  
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TIIVISTELMÄ  
Täysjyväviljan saannilla on käänteinen yhteys sydän- ja verisuonitautien 
esiintymiseen ja niiden aiheuttamiin kuolemiin, joskaan 
vaikutusmekanismeja ei täysin tunneta. Tässä väitöskirjatyössä on tutkittu 
täysjyvärukiin saannin biomarkkereita sekä ruisleipää runsaasti sisältävän 
ruokavalion vaikutuksia plasman LDL-kolesterolipitoisuuteen sekä LDL- 
partikkelien hapettumisherkkyyteen. Erityisen kiinnostuksen kohteena ovat 
alkyyliresorsinolit, ruis- ja vehnänjyvien uloimmissa kuorikerroksissa 
(leseessä) sijaitsevat fenoliset yhdisteet. Alkyyliresorsinolit imeytyvät 
ohutsuolesta verenkiertoon pian aterian jälkeen, minkä vuoksi niiden 
plasmapitoisuutta on ehdotettu biomarkkeriksi täysjyvärukiin/-vehnän 
saannista. Alkyyliresorsinolien tiedetään myös metaboloituvan maksassa 
kahdeksi aineenvaihduntatuotteeksi [3-(3,5-dihydroksifenyyli)1-propaani-
happo, DHPPA ja 3,5-dihydroksibentsoehappo, DHBA], jotka on pystytty 
tunnistamaan verestä ja virtsasta. 
Tässä väitöskirjatyössä määritettiin ensimmäistä kertaa DHPPAn ja 
DHBAn kineettiset parametrit plasmasta ja virtsasta 15 terveeltä 
koehenkilöltä ruisleipä-annoksen (6 siivua, 198 g) nauttimisen jälkeen. 
Saadut tulokset puoltavat DHPPAn ja DHBAn sopivuutta biomarkkereiksi 
täysjyvärukiin saannista ja lisäksi niiden puoliintumisaika plasmassa on 
pidempi kuin alkyyliresorsinolien. DHPPAn ja DHBAn hitaampi 
poistuminen verestä mahdollistaa korkeammat plasmapitoisuudet 
paastoverinäytteissä, mikä voi olla erityisen hyödyllistä silloin kun tutkitaan 
vain vähän täysjyväruista nauttivien henkilöiden näytteitä. 
Laboratoriokokeissa alkyyliresorsinoleilla on havaittu antioksidatiivista 
aktiivisuutta, mutta vastaavia vaikutuksia ihmisellä ei ole tiedossa. Koska 
ruokavaliosta saatujen alkyyliresorsinolien yhtenä kuljettimena 
verenkierrossa toimivat LDL-partikkelit, mahdollinen antioksidanttivaikutus 
voisi suojata LDL-partikkeleita hapettumiselta. LDL-partikkelien 
hapettumisella on yhtymäkohtia ateroskleroosin syntyprosessiin ja siksi 
hapettumisen estäminen oli kiinnostava tutkimuskohde ja -tavoite tässä 
väitöskirjatyössä. Lisäksi tavoitteena oli määrittää ruisleipään 
leipomisvaiheessa lisättyjen kasvisterolien kyky laskea plasman LDL-
kolesterolipitoisuutta, joka on merkittävä sydän- ja verisuonitautien 
riskitekijä. 
Ruisleivän saannin vaikutuksia plasman LDL-kolesterolipitoisuuteen sekä 
LDL-partikkelien hapettumisherkkyyteen tutkittiin 63 terveellä koehenkilöllä 
kuuden viikon mittaisessa ruisleipä-interventiossa. Intervention aikana 
koehenkilöiden ruisleipäannosta vaihdeltiin muun ruokavalion pysyessä 
ennallaan. Vertailujakson ruokavaliosta oli poistettu kokonaan ruis- ja 
täysjyvävehnätuotteet, kun taas ruisjakson aikana ruokavalio sisälsi 
ruisleipää päivittäin; ensin 3 siivua (99 g/pv) kahden viikon ajan, ja tämän 
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jälkeen 6 siivua (198 g/pv) kahden viikon ajan. Lisäksi puolella 
koehenkilöistä (n = 32) ruisleipä sisälsi lisättyjä kasvisteroleja, toisen puolen 
(n = 31) saadessa vastaavaa ruisleipää, mutta ilman kasvisterolilisäystä 
(kontrolli). Verinäytteet otettiin kunkin jakson päätteeksi. Verinäytteistä 
eristettyjen LDL-partikkelien hapettumisherkkyys määritettiin mittaamalla 
hapettumisen viiveaika sekä hapettumistuotteiden (konjugoituneiden 
dieenien) muodostumisnopeus vertailu- ja ruisjakson jälkeen. Näiden 
kahden aikapisteen mittaustuloksia vertailtaessa voitiin todeta LDL-
partikkelien hapettumisherkkyyden vähentyneen merkitsevästi (P < 0.001) 
ruisleipää sisältäneen ruokavalion aikana. Lisäksi LDL-partikkelien 
alkyyliresorsinolipitoisuus nousi merkitsevästi (P < 0.001). 
Alkyyliresorsinolipitoisuus ei kuitenkaan näyttänyt olevan yhteydessä 
mitattuun hapettumisherkkyyteen mikä viittaisi siihen, että 
alkyyliresorsinolit eivät toimineet ainakaan tärkeimpinä antioksidantteina 
LDL-partikkeleissa. Tästä huolimatta ei voida sulkea pois mahdollisuutta 
alkyyliresorsinolien osallisuudesta LDL-partikkelien hapettumisherkkyyden 
vähentämiseen. Kasvisteroli- ja kontrolliryhmien välillä ei havaittu 
merkitsevää eroa LDL-partikkeleiden hapettumisherkkyydessä. Sitä vastoin 
kasvisteroliryhmään kuuluvien koehenkilöiden plasman LDL-
kolesterolipitoisuus laski merkitsevästi kontrolliryhmään verrattuna 
kummankin ruisleipäannoksen jälkeen. Näin ollen, kasvisterolien lisääminen 
ruisleipään näytti entisestään lisäävän täysjyvärukiin terveysvaikutuksia.  
Väitöskirjatyö koostuu kineettisestä tutkimuksesta ja ruisleipä-
interventiosta. Yhteenvetona voidaan todeta, että kineettinen tutkimus 
puoltaa alkyyliresorsinolien aineenvaihduntatuotteiden DHPPAn ja DHBAn 
soveltumista biomarkkereiksi täysjyvärukiin saannista tarjoten hyvän 
apuvälineen – alkyyliresorsinolien rinnalle – viljakuidun terveysvaikutusten 
tutkimiseen. Verrattuna alkyyliresorsinoleihin, DHPPAn ja DHBAn etuna on 
pidempi puoliintumisaika plasmassa. Ruisleipä-interventiossa puolestaan 
osoitettiin, että ruisleipää runsaasti sisältävä ruokavalio vähentää LDL-
partikkelien in vitro hapettumisherkkyyttä, minkä lisäksi plasman LDL-
kolesterolipitoisuus aleni merkitsevästi niillä koehenkilöillä, joiden 
ruisleivässä oli lisättyjä kasvisteroleja. Uusimpien meta-analyysien tuloksiin  
verrattuna, ruisleipä-kasvisteroliyhdistelmä osoittautui yhtä tehokkaaksi 
LDL-kolesterolin laskijaksi kuin kasvisterolit yleensä. Kasvisterolien 
lisääminen ruisleipään näyttää siten parantavan entisestään ruisleivän 
hyödyllisiä terveysvaikutuksia ja on huomionarvoinen seikka kuluttajien 
ruokavalinnoissa, kuten myös kehitettäessä ruokavalioita sydän- ja 
verisuonitautien ehkäisemiseksi. 
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ABBREVIATIONS 
ApoA1  apolipoprotein A1 
ApoB  apolipoprotein B  
AUC  area under the curve 
Cmax  maximum plasma concentration  
CVD  cardiovascular disease 
C15:0 - C25:0 alkylresorcinol homologues with respective carbon
  (alkyl) chain lengths 
DHBA  3,5-dihydroxybenzoic acid 
DHPPA  3-(3,5-dihydroxyphenyl)-1-propanoic acid 
DPPH  2,2-diphenyl-1-picrylhydrazyl 
dw  dry weight 
EDTA  ethylenediaminetetraacetic acid 
ERmax  maximum urinary excretion rate (µmol/h) 
GCMS  gas chromatography-mass spectrometry 
HDL-C  high-density lipoprotein cholesterol 
HPLC-CEAD high-performance liquid chromatography with  
  coulometric electrode array detector 
LDL-C  low-density lipoprotein cholesterol 
n.d.  not determined / not detectable 
PS  plant sterol 
PUFA  polyunsaturated fatty acid 
ROS   reactive oxygen species 
SD  standard deviation 
SEM  standard error of the mean 
TC  total cholesterol 
TG  triacylglycerol 
tmax  time of reaching maximum plasma concentration or 
  maximum urinary excretion rate 
t1/2  half life 
VLDL  very low-density lipoprotein 
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1 INTRODUCTION 
Epidemiological studies have consistently shown lower risk of cardiovascular 
disease (CVD) for humans with high habitual intake of whole-grain cereals or 
cereal fiber [1-4]. Furthermore, a large European prospective study reported 
that cereal fiber intake is associated with reduced mortality from circulatory 
diseases [5]. Since CVD causes the majority of premature deaths in Europe at 
present [6], taking advantage of the protective role of whole grains and cereal 
fiber and uncovering the underlying mechanism are important research targets. 
Dietary prevention and treatment of CVD is essentially focused on lowering of 
plasma low-density lipoprotein cholesterol (LDL-C), a well-established lipid risk 
factor for CDV [6, 7]. In addition, oxidation of LDL particles has been linked to 
atherosclerosis and CVD, and therefore, attempts to prevent oxidation of LDL 
are essential [8, 9], Noteworthy is, however, that in human circulation, high-
density lipoprotein (HDL) has been reported to be able to protect LDL against 
oxidation, and therefore, the level as well as the functionality of HDL should not 
be diminished by dietary means or other treatment [10]. 
In dietary intervention settings, intake of whole grains or cereal fiber over 3 - 
4 weeks has induced improvements in cardiovascular risk factors by lowering 
serum total cholesterol (TC) and LDL-C [11-13]. Soluble fiber of the cereals was 
considered to cause the observed hypocholesterolemic effect [12] and one 
suggested mechanism was increased excretion of bile acids [13]. However, in 
addition to being a source of dietary fiber, whole grains are also a rich source of 
diverse nutrients and bioactive phytochemicals [14-16], most of which are 
located within the cereal bran [17]. Therefore, it can be assumed that while 
cereal fiber plays an important role, bioactive substances also contribute to the 
overall in vivo effect. This was also noted in a prospective study, as women who 
consumed cereal fiber from whole grains had lower all-cause mortality than 
women consuming similar amounts of cereal fiber primarily from refined grains 
[18]. This finding suggests that the protective effect was due to bran-associated 
phytochemicals or other nutrients, which were lacking from the refined grain 
fiber [18].  
Alkylresorcinols are rye/wheat bran-associated phytochemicals, which evoke 
dual interest in human nutrition. Firstly, the intact alkylresorcinols in human 
plasma samples are suggested to serve as a biomarker for whole-grain 
rye/wheat intake, e.g., in epidemiological studies when evaluating associations 
between dietary whole grains and certain diseases [19-21]. Indeed, 
alkylresorcinols have been studied in this respect for ten years [21], while their 
less investigated metabolites appear promising candidate biomarkers as well, 
and therefore call for further examination. Secondly, rye bread, with a reported 
average consumption of 85 g/d [22], is the main dietary source of whole grains, 
cereal fiber, and alkylresorcinols in the Finnish population. Many different 
bioactivities are documented for alkylresorcinols in vitro [23], but these have 
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not been studied  in humans after dietary intake. Whether alkylresorcinols play 
a role in the reduction of cardiovascular risk factors among whole-grain 
consumers is unknown.  
Plant sterols (PSs) are natural constituents in vegetable oils, seeds, and 
grains [24]. In humans, PSs documentedly lower LDL-C [25, 26] and are 
therefore industrially incorporated into several foods such as dairy products and 
spreads. Inclusion of PSs in the diet is recommended for cardiovascular risk 
reduction [27]. Moreover, consumption of PSs have been shown to be safe [28-
31], except for rare cases of sitosterolemia [32]. The efficacy of PSs to lower 
LDL-C can, however, be impaired by the food matrix. It is therefore crucial that 
the chosen food carrier is suitable for the transport and release of PSs into the 
intestine, where these substances can compete with dietary and biliary 
cholesterol for absorption, resulting in lower serum LDL-C [33]. Enrichment of 
rye bread with PSs is novel and may, in theory, further improve the health-
promoting effect of whole-grain rye, but the suitability and efficacy of rye bread 
as a food carrier for PSs remain to be elucidated. 
Our curiosity towards the new candidate biomarkers for whole-grain 
rye/wheat intake together with our interest in determining whether 
alkylresorcinols induce health effects in humans inspired us to examine the 
kinetics of alkylresorcinol metabolites and to conduct a dietary intervention 
with special emphasis on the effects of rye bread intake on plasma LDL; these 
studies together comprise the present thesis. 
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2 REVIEW OF THE LITERATURE 
2.1 ALKYLRESORCINOLS IN DIETARY SOURCES AND 
ESTIMATED INTAKE 
2.1.1 ALKYLRESORCINOLS 
Essential dietary intake of alkylresorcinols comes from foods containing whole-
grain rye/wheat and consists of 5-alkylresorcinols [20, 34], to which the term 
alkylresorcinols refers throughout the study. Even though our expectations for 
potential effects of alkylresorcinols on humans are positive, the initial interest 
towards alkylresorcinols emerged decades ago from the worrisome observation 
that alkylresorcinols in cattle feed caused inhibition of growth and decrease of 
appetite in animals; a rapid determination method for alkylresorcinols was 
therefore considered desireable [35, 36]. 
Alkylresorcinols belong to a large group of phenolic lipids. Structurally, they 
consist of a 1,3-dihydroxybenzene ring (resorcinol), which is alkylated at 
position 5 by a saturated, odd-numbered hydrocarbon side-chain consisting of 
13 to 27 carbon atoms (C13:0 - C27:0) (Figure 1). The existence of water-
soluble and -insoluble groups in the molecule give alkylresorcinols an 
amphiphilic nature [23]. The octanol/water partition coefficient (log Po/w) 
values of alkylresorcinols are between 7.0 and 13.4, the hydrophobicity 
increasing with increasing chain length [20, 37]. In cereals, alkylresorcinols are 
present as mixtures of homologs with different chain lengths.  
 
Figure 1. Chemical structure of alkylresorcinol. R = alkyl chain consisting of 15 - 25 carbons. 
 
Alkylresorcinols are formed by type III polyketide synthases [38]. In cereals, 
they are detected already during kernel development, and thereafter, the 
amounts decrease as the grain matures [39-41]. One explanation for the 
decrease is a dilution effect due to an increase in starch and protein proportions 
in a growing grain [39]. Alkylresorcinols are suggested to serve as 
phytoanticipins in the cereal kernels, thus being present for defensive purposes. 
This viewpoint is supported by the in vitro antimicrobial properties [23, 42-44] 
as well as by the specific bran-associated accumulation of alkylresorcinols in the 
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outer layers, protecting the seed [39, 45]. The exact location of alkylresorcinols 
in a cereal kernel has been elucidated to be in the intermediate layer between 
the testa and pericarp, containing 99% of the alkylresorcinols [46]; see Figure 
2, which illustrates the structure of a rye kernel.  
 
Figure 2. Structure of a rye kernel. Alkylresorcinols are located in the outer layers, between the 
testa and pericarp. Source: KAMPFFMEYER Food Innovation GmbH; www.grain-
gallery.com 
For the quantitative determination of alkylresorcinols, different extraction 
methods preceding the chromatographic analysis [47] are required for 
unprocessed vs. processed cereals. The extractability of alkylresorcinols is 
equivalent with acetone, ethyl acetate, and methanol in unprocessed cereal 
samples [45], but the non-polar acetone and ethyl acetate are not suitable for 
extracting alkylresorcinols from bread [34]. Previously, the baking process was 
thought to destroy or reduce alkylresorcinols, as only low amounts were 
detected in bread [40, 48]. However, later experiments revealed that 
alkylresorcinols remain stable during food processing [34, 49, 50], but probably 
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form complexes with amylose, and therefore a complete recovery can be 
obtained by using hot 1-propanol:water (3:1, v/v) [34]. Interestingly, 
alkylresorcinols can, in turn, affect the baking of bread. High amounts of added 
alkylresorcinols inhibit the activity of baker's yeast, resulting in a lower volume 
and more compact structure of wheat bread than that of other breads with lower 
levels of added alkylresorcinols [51]. However, addition of rye bran, which 
contains natural levels of alkylresorcinols, does not inhibit the activity of baker's 
yeast [51]. Other properties of alkylresorcinols will be discussed in Section 2.3. 
2.1.2 ALKYLRESORCINOLS IN CEREALS 
2.1.2.1 Rye 
The alkylresorcinol contents of rye grains (Secale cereale L.) vary according to 
the cultivar and environmental factors, reported values on a dry weight basis 
(dw) being 360 - 3200 µg/g [20] and most often around 700 - 1100 µg/g [20, 
45, 48, 52-56]. If calculated without the starchy endosperm, rye bran alone 
possesses a very high alkylresorcinol content, 2034 - 2753 µg/g [55, 56]. 
Alkylresorcinol homologs, consisting of carbon chain lengths C15:0 - C25:0, are 
present in rye, and of these C19:0 is the most abundant [20]. Characteristic to 
rye, the C17:0/C21:0 ratio is near 1.0 [57], although higher values like 1.5 - 1.9 
can be detected as well [48, 55]. Treatment with herbicides at nonoptimal 
growing temperatures has been shown to increase total alkylresorcinol 
concentration and decrease the proportion of long-chain (C23:0 - C25:0) 
homologs [58]. An example of a typical distribution of alkylresorcinol homologs 
in rye [34] is shown in Figure 3. 
 
Figure 3. Typical percentage distribution of alkylresorcinol homologs C15:0 - C25:0 in rye. 
Modified from [34]. 
0
5
10
15
20
25
30
35
C15:0 C17:0 C19:0 C21:0 C23:0 C25:0
1 
25 
32 
22 
10 10 
%
 o
f 
to
ta
l a
lk
yl
re
so
rc
in
o
ls
 
 
17 
2.1.2.2 Wheat 
Wheat (Triticum aestivum L.) has been reported to contain alkylresorcinols in 
amounts (per dw) of 317 - 1430 µg/g [20, 52, 56, 59]. Wheat bran contains 2388 
- 3630 µg/g of alkylresorcinols [55, 56], while refined white flour contains only 
20 - 50 µg/g [60]. Alkylresorcinol contents were found to possess a significant, 
negative correlation with 1000-kernel weight, which is a measure of kernel mass 
[59]. This association is suggested to be due to smaller kernels after a dry 
growth season, and thus, proportionally higher alkylresorcinol contents. Factors 
affecting alkylresorcinol contents and homolog composition were listed to be 
year, location, weather condition, wheat variety, and to a lesser extent soil 
composition, fertilization, and pesticide treatment [59]. On the other hand, no 
correlation was found between alkylresorcinol contents in wheat and weather 
conditions (temperature, P = 0.792; precipitation, P = 0.939) in another 
analysis using the same samples [61]. In wheat, the most abundant 
alkylresorcinol homolog is C21:0, and the C17:0/C21:0 ratio is about 0.10 [34, 
56, 57, 59, 62]. An example of alkylresorcinol homolog distribution in wheat 
[55] is shown in Figure 4. 
 
 
Figure 4. Typical percentage distribution of alkylresorcinol homologs C15:0 - C25:0 in wheat. 
Modified from [55]. 
Of the other wheat species, durum wheat (Triticum durum L.) and spelt wheat 
(Triticum spelta L.) have been reported to contain alkylresorcinols in amounts 
of 194-687 and 490-819 µg/g of dw, respectively, the homolog C21:0 being the 
most abundant in both species [34, 50, 62]. In durum wheat, the homolog C17:0 
could not be detected [34] or was found only in minute amounts, with the 
C17:0/C21:0 ratio being as low as 0.01 [62]. Figure 5 illustrates an 
alkylresorcinol homolog distribution of durum wheat based on two reports [50, 
62]. For spelt wheat, the alkylresorcinol homolog distribution was similar to 
that of wheat [34, 59, 62]. 
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Figure 5. Typical percentage distribution of alkylresorcinol homologs C15:0 - C25:0 in durum 
wheat. Modified from [50, 62]. 
2.1.2.3 Triticale 
Triticale (x Triticosecale) is a hybrid cereal of wheat and rye. The alkylresorcinol 
content (per dw) has been reported to be 439 - 647 µg/g [34], and the homologs 
C19:0 and C21:0 to equally comprise the majority of alkylresorcinols, while 
C15:0 could not be detected. An example of alkylresorcinol homolog distribution 
in triticale [34] is shown in Figure 6. 
 
 
Figure 6. Typical percentage distribution of alkylresorcinol homologs C15:0 - C25:0 in triticale. 
Modified from [34]. 
2.1.2.4 Barley 
Only small amounts of alkylresorcinols (per dw) are found in barley (Hordeum 
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contents of a commercial barley bran product in our laboratory and obtained a 
value of 100 µg/g (unpublished results). Interestingly, the alkylresorcinol 
content in barley has been reported to correlate positively with 1000-kernel 
weight [63], contrary to in wheat [59]. The alkylresorcinol homolog distribution 
(Figure 7) differs from other cereals in C25:0 generally being the most 
abundant homolog of those detected (C17:0-C25:0) [34, 63]. However, in one 
report barley was not found to contain C25:0 at all [52], and in another report 
C21:0 was the major alkylresorcinol homolog, followed by C19:0 and C25:0 [64]. 
In our analysis of barley samples, C25:0 was the most abundant homolog (data 
not shown), in agreement with two other reports [34, 63]. 
 
 
Figure 7. Typical percentage distribution of alkylresorcinol homologs C17:0 - C25:0 in barley. 
Modified from [34, 63]. 
2.1.2.5 Other cereals 
Edible parts of oat, rice, millet, and corn are reported not to contain 
alkylresorcinols [34, 52, 65], while buckwheat may contain small amounts [52] 
or none [34]. 
2.1.3 ALKYLRESORCINOLS IN CEREAL-BASED FOODS 
Rye bread is a particularly rich dietary source of alkylresorcinols, and, because 
of its high consumption (85 g/d [22]), also the most relevant food source of 
alkylresorcinols in Finland. Depending on the amount of whole-grain flour 
and/or added rye bran used for baking, the alkylresorcinol content (per dw) may 
vary widely, being 197 - 707 µg/g in soft rye breads [34, 55, 57], and 490 - 1007 
µg/g in crisp breads [34, 57]. Furthermore, pasta containing rye bran has been 
reported to provide an alkylresorcinol content of 262 - 402 µg/g [34, 57], the 
value for breakfast rye cereals being 721 µg/g [55]. Rolled rye grains are 
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comparable with whole-grain rye and possess an alkylresorcinol content of 698 
µg/g [34].  
Whole-grain wheat is another important dietary source of alkylresorcinols. 
The consumption of wheat in Finland is threefold that of rye (46.4 vs. 16.1 kg 
per capita in 2010, respectively)[66], but in contrast to rye, wheat is usually not 
consumed in whole-grain form. Instead, foods from refined wheat flour are 
mostly available, and special food products made of wheat bran are sold 
separately. The alkylresorcinol contents (per dw) of soft wheat breads vary from 
nondetectable amounts to 332 µg/g, while those of crisp breads and digestive-
type biscuits are 58 - 420 µg/g [34, 57]. A sample of spaghetti has been found to 
provide 154 µg/g of alkylresorcinols [57]. The highest alkylresorcinol contents 
among wheat products are found in wheat bran-based breakfast cereals, the 
reported values ranging from 558 µg/g (Weetabix) to 1784 µg/g (All Bran) [34]. 
Of other relevant food sources, alkylresorcinol content in muesli is 124 - 299 
µg/g [55, 57] and spelt wheat flakes 657 - 789 µg/g [56]. The actual importance 
of a certain food as a dietary source of alkylresorcinols depends on individual 
food consumption patterns. Barley and triticale normally comprise a neglible 
portion of dietary cereal consumption (1.4 kg per capita in 2010 for barley [66]), 
thus not being essential dietary sources of alkylresorcinols. The alkylresorcinol 
contents of some cereal foods are listed in Table 1. 
Table 1. Alkylresorcinols in cereal foods. 
Food product 
Alkylresorcinol content 
µg/g dry weight 
Reference 
Rye bread, soft 197 - 707 [34, 57] 
Rye crisp bread 490 - 1007 [34, 57] 
Pasta containing rye bran 262 - 402 [34, 57] 
Breakfast cereals from rye 721 [55] 
Rolled rye grains  698 [34] 
Wheat bread, soft n.d. - 332 [34, 57] 
Wheat crisp bread and biscuits 58 - 420 [34, 57] 
Spaghetti containing whole-grain wheat 154 [57] 
Wheat bran-based breakfast cereals  558 - 1784 [34] 
Muesli  124 - 299 [55, 57] 
Spelt wheat flakes 657 - 789 [56] 
Whole-grain pasta from durum wheat 215 - 270 [50] 
2.1.4 ESTIMATED DIETARY INTAKE OF ALKYLRESORCINOLS 
The intake of alkylresorcinols is highest in Northern and Eastern Europe 
because rye bread is frequently consumed in these areas. The average per capita 
intake of alkylresorcinols has been estimated by using food supply data or food 
consumption data [67]. Food supply data were obtained by converting first the 
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amounts of milled rye/wheat (during a certain year) to per capita amounts and 
then multiplying this value by the average alkylresorcinol content of that cereal. 
According to this method, the intake of alkylresorcinols was highest in Finland, 
39.8 mg/d; followed by Denmark, 37.1 mg/d; Norway, 18.5 mg/d; Sweden, 17.5 
mg/d; and the UK, 11.9 mg/d [67]. In the alternative method utilizing food 
consumption data, the individual food records (in Sweden) or the household 
shopping data (in the UK) were supplemented by data of average alkylresorcinol 
concentrations based on a typical recipe for the food in question. According to 
this data, the mean intake of alkylresorcinols in Sweden was 22.9 mg/d and in 
the UK 11.8 mg/d, while the highest individual intakes were above 100 mg/d in 
both countries [67]. About half of the UK subjects and 3% of the Swedish 
subjects did not consume alkylresorcinol-containing foods at all. The Swedish 
data were further analyzed and the intake of alkylresorcinols was found to be 
higher in males than females (26.4 vs. 19.6 mg/d), which was suggested to 
indicate higher energy intake. On the other hand, alkylresorcinol intake was 
significantly higher in the older age groups in both genders, which, in turn, was 
probably not due to energy intake, but rather to higher typical consumption of 
cereals among older people [67]. The estimated alkylresorcinol intakes in 
different countries are shown in Figure 8. 
 
  
Figure 8. The estimated mean alkylresorcinol intakes in the UK, Sweden, Norway, Denmark, and 
Finland. Modified from [67]. 
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2.2 ABSORPTION, METABOLISM, AND EXCRETION OF 
ALKYLRESORCINOLS IN HUMANS 
2.2.1 ABSORPTION OF ALKYLRESORCINOLS AND OCCURRENCE IN 
HUMAN CIRCULATION  
Ileal absorption of alkylresorcinols begins rapidly after dietary intake [68] and 
has been noted to be reasonably stable regardless of the dose [69, 70]. 
Approximately 60% of the ingested dose is absorbed in the intestine [69]. The 
absorbed alkylresorcinols are transported in chylomicrons via the lymphatic 
system to the circulation and liver [71]. Plasma levels of alkylresorcinols vary 
widely even at steady state, the mean overnight fasting levels being 37.8 - 388 
nmol/L with a moderate to high rye intake [19, 72, 73], and 943 nmol/L with an 
extremely high (483 g/d) rye intake [74]. Intake of a high single dose of rye bran 
(120 g) induces mean postprandial plasma alkylresorcinol levels of 3365 nmol/L 
[68]. The majority of the plasma alkylresorcinols are carried by lipoproteins 
VLDL, HDL, and LDL, with respective shares of 46%, 33%, and 20% [71]. In the 
circulation, alkylresorcinols can also be incorporated into erythrocyte 
membranes, the average concentrations being 62.5 - 69.6 nmol/L of packed 
erythrocytes during constant, moderate intake of whole-grain rye/wheat [72]. 
The longer chain alkylresorcinol homologs (C23:0 - C25:0) tend to accumulate 
based on observations that they are present in higher proportions in plasma and 
erythrocyte membranes than in rye bread [68, 72, 73]. 
Determination of kinetic parameters for plasma alkylresorcinols indicates 
two peak concentrations, the lower of which occurs at 2.8 h and the higher at 6.6 
h after rye intake [68]. The terminal elimination t1/2 of plasma alkylresorcinols 
is relatively short, 4.8 h, indicating fairly rapid clearance of alkylresorcinols 
from the circulation. Most of a single dose is excreted within 24 h of ingestion 
[68]. 
Plasma alkylresorcinols hardly ever reach zero, even after avoiding whole-
grain products for a certain time (wash-out period) in trials. This is at least 
partly due to the storage of dietary alkylresorcinols in adipose tissue and 
liberation during low or no intake [75], in line with an earlier suggestion [71].  
Table 2 summarizes the essential findings on the absorption of 
alkylresorcinols and their occurrence in human circulation. 
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Table 2. Summary of essential findings on the absorption of alkylresorcinols and their 
occurrence in human circulation. 
Issue Year Reference 
Alkylresorcinols are present in human plasma 2002 [19] 
Dietary alkylresorcinols are absorbed by humans, 
absorption rate is not affected by dose or meal frequency 
2003 [69] 
Alkylresorcinols are present in human erythrocyte membranes 2005 [72] 
Plasma alkylresorcinols correlate with rye bread intake 2005 [73] 
Determination of alkylresorcinol kinetics; half-life 4.8 h 2006 [68] 
Alkylresorcinols are carried by lipoproteins 2007 [71] 
Clear dose-response of plasma alkylresorcinols to dietary intake, 
suggesting fairly stable intestinal absorption regardless of dose  
2006 [70] 
Alkylresorcinols are stored in adipocytes  2007 [75] 
2.2.2 METABOLISM OF ALKYLRESORCINOLS 
Based on the literature and structural similarities with tocopherols, the hepatic 
metabolism of alkylresorcinols is expected to include ω-hydroxylation of the 
side-chain, oxidation to yield carboxylic acid, and β-oxidation to shorten the 
alkyl tail and yield water-soluble compounds [20, 76]. The reported ability of 
alkylresorcinols to interfere with the metabolism of γ-tocopherol in cultured 
hepatocytes and in rats supports this idea [77]. In humans, two alkylresorcinol 
metabolites, 3-(3,5-dihydroxyphenyl)-1-propanoic acid (DHPPA) and 3,5-
dihydroxybenzoic acid (DHBA), were identified in urine [78] and in plasma 
[79]. Both free and conjugated forms (glucuronide or sulfate) of the metabolites 
are present in both of these body fluids [78, 79]. The chemical structure of the 
two alkylresorcinol metabolites DHPPA and DHBA is shown in Figure 9.  
 
  
Figure 9. Chemical structure of the alkylresorcinol metabolites. 3-(3,5-dihydroxyphenyl)-1-
propanoic acid (DHPPA) on the left; 3,5-dihydroxybenzoic acid (DHBA) on the right. 
Reproduced with permission from Sigma-Aldrich Co. 
Review of the literature 
24 
2.2.3 URINARY EXCRETION OF ALKYLRESORCINOL METABOLITES  
DHPPA and DHBA are the major urinary excretion forms of the ingested 
alkylresorcinols, although small amounts of intact alkylresorcinols can be found 
in urine after a high single intake (150 mg) of alkylresorcinols [78].  
Increasing the dose of ingested alkylresorcinols has been shown to increase 
the urinary excretion of DHPPA and DHBA significantly (P < 0.001), albeit the 
total urinary recovery/24 h of these metabolites is significantly (P < 0.020) 
decreased simultaneously, from 89.0% to 44.6% following alkylresorcinol doses 
of 85 µmol and 342 µmol, respectively [70]. Whether a high alkylresorcinol dose 
can cause a change in the elimination route from urinary to biliary excretion or 
is incompletely excreted during a 24-h urine collection is unclear [70].  
Conjugation of metabolites increases their water solubility for urinary 
excretion [78, 80]. Conjugation of DHPPA and DHBA with sulfates accounts for 
15% for both metabolites, while conjugation with glucuronides comprises 39% 
for DHPPA and 18% for DHBA, following a daily intake of 170 µmol (66 mg) of 
alkylresorcinols [81]. Therefore, the excretion of the less hydrophilic DHPPA is 
more dependent on conjugation than that of the more hydrophilic DHBA [81]. 
The balance between conjugation with sulfates vs. glucuronides may be affected 
by the ingested dose of alkylresorcinols [81], similarly to some other compounds 
[82], or by the lipid solubility of the substrate or even by the substrate specificity 
of the transferases involved [83].  
2.3 PROPERTIES OF ALKYLRESORCINOLS AND THEIR 
METABOLITES 
2.3.1 ALKYLRESORCINOLS AS A BIOMARKER FOR INTAKE OF WHOLE-
GRAIN RYE/WHEAT 
During the past 10 years alkylresorcinols in plasma have been suggested to be a 
suitable biomarker for whole-grain rye/wheat intake [19-21, 84]. Ideally, 
alkylresorcinols as a biomarker could be utilized as an objective indicator of 
whole-grain rye/wheat intake when studying the effects of these foods on risk of 
certain diseases in large populations. A reliable biomarker could additionally 
overcome the potential bias associated with self-reported dietary intakes, those 
being under-/overestimation of the consumed amounts or intake frequencies 
[85, 86], as well as incorrect identification of whole-grain products in one's diet 
[84, 87]. Furthermore, one study explored the potential of alkylresorcinols as 
surrogate markers by testing the association between plasma alkylresorcinols 
and endometrial cancer, but found no correlation [88].  
The described quantification methods for plasma alkylresorcinols include 
GC/MS and LC/MS/MS analysis after varying extents of sample preparation 
[19, 89, 90]. In plasma samples, alkylresorcinol homologs can reflect the cereal 
source of alkylresorcinols. The C17:0/C21:0 ratio is characteristically around 0.6 
- 0.8 after rye bread intake and 0.1 - 0.5 after whole-grain wheat intake [71, 73]. 
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The suitability of alkylresorcinols as a biomarker for whole-grain rye/wheat 
intake is supported by several studies reporting correlation coefficients between 
plasma alkylresorcinols and cereal-based food items, these being summarized in 
Table 3. In these studies, correlations between plasma alkylresorcinols and 
intake of cereal fiber [91-93] or rye/wheat whole grains [91, 93] have been 
observed in humans consuming their habitual diet. Also, under dietary 
intervention settings plasma alkylresorcinols have been found to correlate with 
the intake of rye bread and insoluble fiber [73] or rye/wheat fiber as well as total 
dietary fiber [94] and whole-grain wheat and total whole grains [95]. In a 
prospective study using nonfasting plasma samples, a modest correlation was 
found between the estimated intake or rye bread and plasma alkylresorcinols 
[96]. Some other studies have noted a response in plasma alkylresorcinols to 
whole-grain rye/wheat intake [68, 70-72, 74]. 
Table 3. Correlation studies on plasma alkylresorcinols and the intake of cereal-based food 
components. 
Food component 
correlating with 
plasma 
alkylresorcinols 
Dietary 
intake 
g/d 
Diet/study 
type 
Dietary 
assesment 
method 
n 
Plasma 
AR 
nmol/L 
    r Reference 
Whole-grain rye  
Whole-grain rye + 
wheat 
Cereal fiber 
29 
 
49 
11 
Habitual FR 51 73 
 0.28* 
 
 0.53*** 
 0.32* 
[91] 
Cereal fiber 10 Habitual FR 56 65.5  0.41** [92] 
Whole-grain cereals 
 
Whole-grain wheat 
 
Cereal fiber 
26 
29 
17 
17 
9 
Habitual 
FR 
FFQ 
FR 
FFQ 
FFQ 
31 55.8 
 0.57* 
 0.54* 
 0.47* 
 0.37* 
 0.56* 
[93] 
Rye bread 
Insoluble fiber 
214 
30 
Intervention FR 39 352 
 0.34* 
 0.39* 
[73] 
Rye/wheat fiber 18 Intervention FR 28 202  0.47*1 [94] 
Whole-grain wheat 
Whole-grains 
- 
- 
Intervention FFQ 252 - 
 0.39*** 
 0.32*** 
[95] 
Rye bread 62.5 Habitual FFQ 360 78  0.25***2 [96] 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
1 r value is based on combined data from baseline, refined grain and whole-grain -periods 
2 non-fasting plasma samples 
AR, alkylresorcinols; r, correlation coefficient; FR, food record; FFQ, food frequency 
questionnaire; -, data missing 
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Besides these studies, other facts supporting the suitability of alkylresorcinols as 
a biomarker for whole-grain rye/wheat intake are the lack of these compounds 
in other foods, stability during cooking, successful absorption in humans in 
response to intake, and detectability in grains, foods, and biological samples 
(see 2.1. and 2.2.). However, limiting the usage are the short elimination t1/2 (4.8 
h) of the plasma alkylresorcinols and the vast interindividual variation in 
plasma levels even after similar intakes (see Section 2.2.1.), potentially resulting 
in a lack of correlation between dietary whole-grains and plasma 
alkylresorcinols and also hindering quantitative estimation of individual whole-
grain rye/wheat intakes. 
Reproducibility studies evaluate whether a single measurement of a 
biomarker can reflect average levels over a longer time period [97]. Plasma 
alkylresorcinols have been reported to possess poor to moderate reproducibility 
over a 2- to 4-month period in individuals consuming theri habitual diet [91, 95, 
98]. In two of these studies, alkylresorcinols correlated with whole-grain 
rye/wheat intake [91, 95]. Good reproducibility for plasma alkylresorcinols has 
been reported only in a 6-week intervention setting with extremely high daily 
intake (483 g/d) of rye bran/whole-grain rye products [74]. 
In conclusion, the suitability of alkylresorcinols as a biomarker for whole-
grain rye/wheat intake has been shown in many studies, and at present it 
appears to be the best option. However, the short t1/2, the large inter-individual 
variation in plasma levels, and the poor to moderate reproducibility as a longer-
term biomarker limit their usefulness. Nevertheless, plasma alkylresorcinols 
could be used to distinguish between high and very low consumers of whole-
grain rye/wheat in epidemiological studies, or as a compliance marker in dietary 
interventions, including whole-grain rye/wheat intake. 
2.3.2 ALKYLRESORCINOL METABOLITES AS POTENTIAL BIOMARKERS 
FOR THE INTAKE OF WHOLE-GRAIN RYE/WHEAT 
Alkylresorcinol metabolites DHPPA and DHBA in plasma and urine are 
suggested to serve as biomarkes for whole-grain rye/wheat intake [78, 99, 100], 
although they have been less extensively investigated than the intact 
alkylresorcinols. Furthermore, in a small study, these metabolites were 
proposed as potential surrogate markers for breast cancer risk, [101] but this 
has not been confirmed in a larger study. The analysis methods for urinary 
metabolites include a rapid and simple HPLC-CEAD [102] as well as a more 
laborious GC-MS method [81], these two being considered methodologically 
equal [103]. Furthermore, for plasma samples an HPLC-CEAD method has been 
described [79]. 
In one of the first studies on alkylresorcinol metabolites in plasma, a 
correlation between the sum of DHPPA + DHBA and intact alkylresorcinols was 
found (P < 0.001, r = 0.686) [79]. Thereafter, a few studies have presented 
correlation coefficients between the intake of cereal-based food items and 
plasma DHPPA/DHBA, these being summarized in Table 4. In plasma samples 
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from subjects consuming a habitual diet, DHPPA and DHBA were found to 
correlate with cereal fiber and rye intake, estimated from 5-day food records 
[99, 104]. When the study subjects were categorized into three levels according 
to their habitual intake of rye, at the highest intake level (68 g/d) plasma 
DHPPA was 44% higher than at the lowest intake level (23 g/d) and 27% higher 
than at the medium intake level  (44 g/d), (P < 0.05 for both), while plasma 
DHBA did not differ significantly between the intake levels [104]. 
Some studies have reported correlation coefficients between the intake of 
cereal-based food items and urinary DHPPA/DHBA; these are summarized in 
Table 4. DHPPA and DHBA, in a 72-h urine collection, have been reported to 
have significant correlations with habitual cereal fiber intake, estimated from 5-
d food records, and according to the author, an intake of 10 g of cereal fiber 
induced urinary excretion of 40.2 and 26.8 µmol/24 h for DHPPA and DHBA, 
respectively [92]. Furthermore these metabolites showed good response to 
different rye intake levels; at the highest level (68 g/d of rye), DHPPA and 
DHBA increased by 50% and 52% relative to the lowest level (23 g/d), and 25% 
and 29% relative to the medium level  (44 g/d), (P < 0.05, for all) [104]. In 
American population with none-to-moderate habitual intakes of whole-grains (0 
- 3 servings/d), and less than 10% of the participants consuming rye, 12-h 
urinary DHPPA excretion (1.3 - 99.4 µmol/12 h) was increased by 67% (P < 
0.0001) by increasing the intake of whole-grains by one serving/d [100]. A very 
recent study on American women consuming habitual diets showed a 
correlation between whole-grain intake (mean 15.9 g/d) and urinary DHPPA, 
even in spot urine samples [105]. In addition, an intervention study revealed a 
clear dose-response relationship between the intake of alkylresorcinols and 
urinary excretion of DHPPA and DHBA, confirming that these metabolites are 
solely derived from alkylresorcinols [70].  
The reproducibility of urinary DHPPA and DHBA measurements over 1 - 3 
years was reported to be poor to modest in spot urine samples, indicating that 
long-term intake of whole-grain cereals cannot be estimated based on a single 
sample [105].  
In summary, additional data are needed concerning DHPPA and DHBA and 
their occurrence in plasma and urine before these compounds can be applied as 
biomarkers. However, relative to determination of alkylresorcinols, a smaller 
sample volume and less sample pretreatment are required. 
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Table 4. Correlation studies on plasma/urinary DHPPA and DHBA and intake of cereal-based 
food components. 
Food component 
correlating with 
alkylresorcinol 
metabolites 
Dietary  
intake 
  g/d 
Diet/ 
study 
type 
Dietary    
assesment     
method 
DHPPA/   
DHBA in  
plasma/ 
urine 
n     r Reference 
Cereal fiber  
 
10 Habitual FR 
901 
942 
5 
6 
0.463*** 
0.411** 
[99] 
Rye 
 
- Habitual FR 
-1 
-2 
-3 
-4 
6 
0 
0.397** 
0.299* 
0.438*** 
0.524*** 
[104] 
Cereal fiber 
 
10 Habitual FR 
40.23 
26.74 
5 
6 
0.402** 
0.359** 
[92] 
Whole-grains 
Cereal fiber 
15.9 
5.8 
Habitual FFQ 
8.45 
3.35 
9 
5 
0.37* 
0.33* 
[105] 
* P < 0.05 
** P < 0.01 
*** P < 0.001 
1  plasma DHPPA (3-(3,5-dihydroxyphenyl)-1-propanoic acid) nmol/L 
2  plasma DHBA (3,5-dihydroxybenzoic acid) nmol/L 
3  urinary DHPPA µmol/24h urine collection 
4  urinary DHBA µmol/24h urine collection 
5  urinary DHPPA µmol/l in spot urine samples 
r, correlation coefficient; FR, food record; FFQ, food frequency questionnaire; -, data missing 
2.3.3 ANTIOXIDANT ACTIVITY OF ALKYLRESORCINOLS  
2.3.3.1 Concept of antioxidants 
Antioxidants are substances that 'when present at low concentrations compared 
to those of an oxidizable substrate, significantly delay or prevent oxidation of 
that substrate' [106]. The oxidizable substrates include lipids, proteins, and 
DNA in biological systems and almost any molecules in food [107]. Antioxidant 
activities include inhibition of formation of reactive oxygen species (ROS) and 
scavenging of free radicals of endogenous/environmental origin [106, 107]. 
Vitamin E is a well-established antioxidant, and because of the structural and 
metabolic similarities between tocopherols and alkylresorcinols, the latter has 
been anticipated to have some antioxidant activity as well [20, 77, 108, 109], 
inspired a variety of in vitro studies, which are discussed below. 
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2.3.3.2 Alkylresorcinols preventing the oxidation of LDL 
An LDL particle contains approximately 1300 molecules of polyunsaturated 
fatty acids (PUFAs), these being susceptible to oxidative modification [110]. 
Considering that oxidatively modified LDL is involved in atherosclerosis [8, 111] 
and that LDL is one of the carriers of alkylresorcinols in human circulation [71], 
the potential of alkylresorcinols to protect LDL from oxidation is an important 
issue. 
An in vitro method by Esterbauer has been widely used to investigate LDL 
oxidation [112]. In this assay, isolated LDL particles are exposed to Cu2+ ions, 
which initiate oxidation of the PUFAs in LDL and cause depletion of 
endogenous antioxidants. This phase is called the lag time and its duration 
determines the oxidation resistance of LDL. Antioxidants are important 
contributors to the duration of lag time, although individual variation is large 
[110]. After the endogenous antioxidants of LDL are depleted, the lag time ends 
and the propagation phase (oxidation of the PUFAs in LDL) begins. The 
oxidation process in the Esterbauer assay is monitored at 234 nm, a wavelength 
characteristically absorbed by conjugated dienes [112]. When evaluating the 
contribution of a certain antioxidant to the oxidation resistance of LDL, the 
compound in question can either be added directly to the assay system or 
consumed orally before blood sampling and isolation of LDL. 
Vitamin E has been described to be the major endogenous antioxidant in 
LDL, also being associated with the oxidation resistance of these particles [110]. 
In vitro enrichment of the assay system with α-tocopherol led to a linear 
increase in the oxidation resistance of LDL [113], as did dietary supplementation 
[110]. Oral consumption of other antioxidants or antioxidant-rich foods has also 
been used to improve oxidation resistance of LDL [114, 115]. 
Recently, alkylresorcinol homologs C15:0 and C17:0 were found to increase 
the resistance of isolated LDL particles to copper-induced oxidation when added 
as pure compounds to the assay system [116]. The tested concentrations were 
2.5 and 25 µmol/L, the former of which could be normally achievable as 
postprandial plasma concentration of alkylresorcinols (C15:0 - C25:0) after a 
high dietary intake of rye (120 g of rye bran flakes) [68], and also as an extreme 
fasting plasma concentration during a habitual diet [91]. It is worth noting, 
however, that rye is not a substantial source of C15:0 alkylresorcinols [20], and 
the effect of the longer chain homologs C19:0 and C21:0 was not tested because 
of solubility problems [116].  
In summary, vitamin E is the major antioxidant in LDL, with an established 
in vitro effect on LDL oxidation resistance. Alkylresorcinols as pure compounds 
have shown some antioxidant activity in LDL oxidation assay, but whether 
dietary consumption of alkylresorcinols improves the oxidation resistance of 
LDL, thus far remains obscure.    
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2.3.3.3 Alkylresorcinols as hydrogen donators 
The ease of hydrogen donation of a compound (a measure of antioxidant 
activity) can be examined in vitro using a relatively stable free radical, 2,2-
diphenyl-1-picrylhydrazyl, (DPPH), and monitoring the absorbance decrease at 
515 nm as a result of this radical being reduced by the examined antioxidant 
[117].  
The hydrogen donation ability of C15:0 - C21:0 alkylresorcinols is lower than 
that observed for ferulic acid or vitamin E [116, 118, 119], which are also present 
in rye [120-122]. The observed relatively poor scavenging activity of 
alkylresorcinols is in line with another report [123], and considering the 
structure of alkylresorcinols, also expected. Phenols with para- and ortho-
dihydroxylic groups are the most effective antioxidants [124], while 
alkylresorcinols contain the two hydroxyl groups at meta-position. 
Furthermore, when extracts from whole-grain bread extracts were studied, the 
observed DPPH-radical reduction was not proportional to the alkylresorcinol 
content of these samples [119], and therefore, the possibility for other 
compound(s) in the samples to contribute to DPPH reduction cannot be ruled 
out. The hydrogen donation ability of the different alkylresorcinol homologs 
(C15:0 - C25:0) was relatively equal [119], which is also expected, as the length 
of the alkyl chain has been reported to affect the lipophility of alkylresorcinols, 
playing a role in the incorporation of alkylresorcinols into the biological 
membranes [125].  
 Overall, the hydrogen donation ability of alkylresorcinols is quite poor, 
suggesting that this mechanism of action is more likely for some other 
compounds in rye than alkylresorcinols.  
2.3.3.4 Alkylresorcinols and ferric ion reduction 
The ferric-reducing ability of plasma is considered a measure of the 'antioxidant 
power' of a compound to reduce ferric ions (Fe3+) to ferrous (Fe2+) form, which, 
at low pH and in the presence of tripyridyltriazine complex, results in an 
increase in absorbance at 593 nm [126]. Alkylresorcinol homologs C15:0 - C21:0 
showed 10-fold lower ferric-reducing ability than ferulic acid [116], suggesting 
that the potential antioxidant activity of alkylresorcinols  would not be mediated 
via this mechanism. 
2.3.3.5 Alkylresorcinols and chemiluminescence inhibition 
In the chemiluminescence method, a radical-luminol system produces emission 
of light, which is measured by a luminometer. An antioxidant acts by inhibiting 
the luminescence. Alkylresorcinols were only weak antioxidants compared with 
tocopherols, and the inhibition of luminescence was not stable [119]. 
Furthermore, when studying extracts from whole-grain rye bread and mixed 
cereal products, the reduction of luminescence was not proportional to the 
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alkylresorcinol contents of the samples, and therefore, it is quite possible that 
the observed antioxidant activity of the bread samples was produced by 
compounds other than alkylresorcinols [119]. 
2.3.3.6 Alkylresorcinols inhibiting oxidation in oil systems 
Antioxidant activity of alkylresorcinols has been studied in different oil systems 
[109, 118, 127, 128]. Alkylresorcinol homolog C17:0, isolated from rye grains and 
used at high concentrations (2.6-20% of total lipids in the assay), inhibited 50-
90% of the linolenic acid oxidation induced by ferrous ions [109]. 
In another study, oils from corn, olive, safflower, sunflower, and soybean 
were incubated at different temperatures with and without added unpurified 
C15:0 alkylresorcinols at concentrations of 0.025%, 0.05% and 0.075% [127]. 
The oil samples with the added alkylresorcinols were found to resist the Cu2+-
induced oxidation of the lipids [127]. However, in later experiments by others, 
purified C15:0 alkylresorcinols were added at concentrations of 0.01%, 0.1% and 
0.5% to sunflower triacylglycerols (TGs), and the oxidation experiments showed 
only negligible inhibitory effects, while α-tocopherol was highly effective at 
concentrations of 0.1% and 0.01% [118]. The authors explained the discrepancy 
between the latter and the previously reported [127] study by the impurity of the 
previously used C15:0 alkylresorcinols (declared to also contain 4-methyl-5-
pentadecylresorcin), as they also found the unpurified C15:0 alkylresorcinols to 
possess a significant antioxidant effect on sunflower oil [118].  
Purified C15:0 alkylresorcinols have, however, in an earlier study shown 
antioxidant activity by inhibiting oxidation of linoleic and linolenic acid at 
concentrations higher than 2.4%, and 1.2%, respectively [128]. The 
concentrations required for the antioxidant activity are higher than those 
occurring naturally in foods or in the human circulation, and therefore, this 
finding may not translate into a practical benefit.  
All in all, these studies do not support a very active role for alkylresorcinols 
as peroxyl radical scavengers. This is consistent with the observation that the 
redox potential of alkylresorcinols is higher than that of PUFAs, and therefore, 
the former cannot compete with the latter for hydrogen donation to peroxyl 
radicals [118]. 
2.3.3.7 Alkylresorcinols as antioxidants in model (liposomes) and 
biological membranes 
Liposomes are cell membrane-resembling, artificially made vesicles consisting 
of a phospholipid bilayer. The membrane of LDL shares similarities with 
liposomal and biological membranes, but consists of a phospholipid monolayer 
and free cholesterol. Alkylresorcinols, with a reportedly high octanol/water 
partition coefficient and an amphiphilic nature, are able to become incorporated 
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into liposomal and biological membranes, thus existing near the PUFAs 
attached to phospholipids [125, 129].  
Alkylresorcinols (C5:0, C15:0, C17:0) were found to reduce the amount of 
ferrous ion-induced peroxidation products in a liposomal lipid bilayer 
membrane [109, 129]. The effective concentrations for 87-100% inhibition in 
the assays were, however, high: 75-85µM for C15:0 and C5:0 [129]. The 
resorcinolic ring (without the carbon chain) was found to be less effective [129]. 
Although the mechanism of antioxidant activity remained somewhat obscure, 
hydrogen donation [129] or stabilization of the liposome membrane [109] by 
alkylresorcinols was suggested to play a role, the latter via restricting contacts 
between PUFA double bonds and the oxidizing agent.  
In another experiment, alkylresorcinol homologs C15:0, C19:0, and C23:0 
were able to inhibit hydrogen peroxide-initiated oxidation of the erythrocyte 
membrane lipids, while C5:0 was not [108]. The antioxidant activity was 
observed at concentrations of 6-60µM, and the effect was dependent on 
alkylresorcinol homolog chain length, test temperature, and preincubation time 
of erythrocytes with alkylresorcinols prior to addition of the oxidizing agent. The 
lack of effect for the shortest homolog C5:0 was thought to be due to inefficient 
incorporation/anchoring of the very short-chain alkylresorcinols into the lipid 
bilayers. On the other hand, the longest homolog C23:0 was the next weakest of 
the tested ones, and this was hypothesized to result from the phenolic group 
being located too far away from the membrane surface. As another potential 
mechanism of protection, the authors suggested that hydrogen bonds between 
alkylresorcinols and phospholipids served as a stabilizing factor for the 
membrane [108].  
In line with previous findings, a recent study showed that oxidation 
resistance of liposome lipids was improved by alkylresorcinol addition during 
liposome preparation [130].   
In summary, the antioxidant activity of alkylresorcinols on different 
membranes depends on the alkyl chain length and presumably involves 
stabilization of the membrane bilayer and/or hydrogen donation by 
alkylresorcinols; the required effective concentrations are high (micromolar). 
2.3.4 OTHER PROPERTIES OF ALKYLRESORCINOLS  
A variety of in vitro bioactivities have been documented for alkylresorcinols. 
Among other activities, these substances are capable of binding to the 
hydrophobic regions of some proteins and modulating their enzymatic activity 
[131]. Medium-chain alkylresorcinol homologs (C15:0 - C19:0) have been 
reported to inhibit the activity of glycerol-3-phosphate dehydrogenase at 
micromolar concentrations [132, 133], while data concerning other homologs 
are missing. This finding could be of biological importance, as the studied 
enzyme is crucial for TG synthesis in adipose tissue and its activity is enhanced 
in obese humans [134]. Additionally, alkylresorcinol homologs C15:0 - C21:0 
were able to prevent accumulation of TGs in cultured adipocytes, the efficacy 
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being associated with the alkyl chain length [132]. A potential explanation 
offered by the authors is incorporation of alkylresorcinols into bilayer 
membranes and interaction with glycerol-3-phosphate dehydrogenase [132]. In 
another study, alkylresorcinols inhibited oxidative activity of soybean 
lipoxygenase on linoleic acid and arachidonic acid, again the activity being 
stronger for longer chain homologs (C21:0 - C23:0) [135]. The suggested 
mechanisms were chain length-dependent penetration of alkylresorcinols into 
the membrane and alkylresorcinol-induced alteration of substrate properties. 
Interaction of alkylresorcinols with biological and liposomal membranes is 
reportedly a complicated property for alkylresorcinols, affecting the shape, 
rigidity, stability, and permeability of the membranes, depending on the way 
alkylresorcinols are added to the system [130, 136-138]. 
Preincubation of cultured human colon cancer cells with alkylresorcinols was 
demonstrated to improve self-protection of these cells against DNA damage 
[116]. The protective effect was observed against hydrogen peroxide as well as 
genotoxic fecal water, and it was inversely related to alkyl chain length (C15:0 - 
C23:0). However, homolog C15:0 at 100 µmol/L showed cytotoxicity against 
these cultured cells [116]. 
Lastly, many reports describe alkylresorcinols to possess antimicrobial 
activity in vitro, in line with their protective function in plants as well as their 
outermost location in the cereal kernel [139-142].  
Taken together, alkylresorcinols possess multifaceted in vitro bioactivities, 
but whether these compounds contribute to the whole-grain rye/wheat-induced 
health effects in humans remains unknown. 
2.4 PLANT STEROLS IN DIET 
PSs are cholesterol-resembling compounds of plant origin. In the human diet, 
the richest natural sources of PSs constitute vegetable oils, cereal products, and 
nuts [24]. In the intestine, PSs inhibit equally the absorption of dietary and 
biliary cholesterol, and the reduction in serum cholesterol is equal to that 
observed with plant stanols at doses around 2 g/d [26, 143, 144]. The 
hypocholesterolemic mechanism is based on the ability of PSs to compete with 
dietary and biliary cholesterol for uptake into mixed micelles in the intestinal 
lumen, after which these compounds are transferred to enterocytes [33, 145]. 
From the enterocytes, most of the PSs are pumped back into the intestinal 
lumen by ATP-binding cassette transporter proteins [33] and only 0.51-1.89%, 
depending on the molecular structure, are normally absorbed [146]. However, 
in patients with a rare lipid disorder called sitosterolemia, PS excretion by these 
transporter proteins is impaired, and the subsequent accumulation is associated 
with premature atherosclerosis [32].  
The estimated habitual intake of PSs has been reported to be around 160-
400mg/d in different populations [147]. In a large European study, habitual PS 
intake – calculated from food frequency questionnaires – varied between 38 and 
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749 mg/d, being inversely associated with serum TC and LDL-C in these 
individuals [148]. Because of the cholesterol-lowering properties of PSs, they are 
also industrially incorporated into various foods like spreads or yoghurts. These 
special foods assist dietary treatment of elevated cholesterol and may contribute 
markedly to cardiovascular risk reduction. While consumption of these foods 
can multiply the intake of PSs, no adverse effects have been reported in healthy 
humans, except for the lowering of serum β-carotene [28, 29, 143]. The food 
matrix plays an important role in transporting and releasing PSs into the 
intestine for the cholesterol-lowering action [149], and this efficacy must be 
evaluated in clinical studies. To our knowledge, PSs have not been incorporated 
into rye bread before, and therefore, no reports exist on the suitability and 
efficacy of rye bread as a food carrier for PSs. Also unknown is whether the 
health-promoting effects of whole-grain rye can be further improved by PS 
enrichment. 
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3 AIMS OF THE STUDY 
The aims of this study were as follows: 
 
1. To explore the kinetics of the alkylresorcinol metabolites DHPPA and DHBA 
in plasma and in urine after the intake of a single dose of rye bread containing a 
known amount of alkylresorcinols, in order to estimate the potential of these 
metabolites as biomarkers for the intake of whole-grain rye (Studies I and II). 
 
2. To investigate with a dietary intervention the effect of rye bread intake on the 
oxidation resistance of isolated LDL particles, and to evaluate the potential role 
of the rye-derived alkylresorcinols as antioxidants within these LDL particles 
(Study III).  
 
3. To examine with a dietary intervention the cholesterol-lowering efficacy of 
PSs, which are incorporated into a novel food carrier, rye bread, in order to 
estimate whether rye bread is a suitable matrix for the transport and release of 
PSs into the intestine, where they are known to inhibit the absorption of 
cholesterol (Study IV).  
 
4. To assess the utilization of alkylresorcinol metabolites as biomarkers for 
dietary compliance (rye bread intake) in a dietary intervention trial (Studies III 
and IV). 
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4 MATERIALS AND METHODS 
4.1 STUDY DESIGNS AND SUBJECTS 
4.1.1 KINETIC STUDY OF ALKYLRESORCINOL METABOLITES IN 
PLASMA AND URINE  (STUDIES I AND II) 
The kinetic study was designed to monitor the appearance of alkylresorcinol 
metabolites DHBA and DHPPA in plasma and urine after a two-day low-
alkylresorcinol diet and overnight fasting, and thereafter following ingestion of a 
single dose of rye bread (198 g) containing 100 mg of alkylresorcinols. Plasma 
samples and all urine were collected at the following time-points: before 
ingestion of rye bread dose (0 h), and at 3, 4, 5, 6, 7, 8, 10, 12, 14, 16 and 25 h 
after ingestion. Additionally, all urine between 16 and 24 h was collected in a 
container. During the study the subjects were provided standardized meals and 
drinks and instructed to avoid consuming any other foods. 
Fifteen healthy subjects volunteered for the kinetic study. The  demographic 
characteristics of the study participants are shown in Table 5. All volunteers 
were provided with written and oral information about the study, and they 
attended a blood screening test. As exclusion criteria, we specified low 
hemoglobin values; < 125 g/L for females or < 135 g/L for males, and the use of 
antibiotics within the past three months. Informed consent was obtained from 
all subjects. The study protocol was approved by the Ethics Committee of 
Helsinki University Central Hospital, Helsinki, Finland, and is registered in 
www.ClinicalTrials.gov under the study ID no. NCT00953836. 
All 15 subjects completed the study and were included in the statistical 
analyses. 
Table 5. Demographic characteristics of the study subjects participating in the kinetic study of 
alkylresorcinol metabolites. Modified from Studies I and II. 
Variable    Mean (±SD) 
n 15 
Gender 
(females/males) 
8/7 
Age (y) 24.3 (5.3) 
Weight (kg) 68.3 (10.9) 
   BMI 22.1 (2.0) 
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4.1.2 DIETARY INTERVENTION  (STUDIES III AND IV) 
The dietary intervention study was a randomized, double-blind, placebo-
controlled trial designed to test the effect of null versus high intake of rye bread 
(without or with added PSs) on plasma lipids and oxidation resistance of 
isolated LDL particles in healthy humans. The suitability of rye bread to act as 
novel food carrier for added PSs for cholesterol-lowering purposes was also 
evaluated. Apart from the specifications regarding the intake of rye bread and 
some other cereals (see details below), the habitual diet was followed 
throughout the trial. Compliance was monitored by utilizing 3-day food diaries 
and by determining plasma DHBA concentration as a biomarker for rye bread 
intake. 
The duration of this trial was six weeks; this consisted of a one-week habitual 
diet period, followed by a one-week baseline period with null intake of rye 
bread, a two-week rye period with 3 slices (99 g/d) of rye bread intake, and 
finally another two-week rye period with a doubled dose (6 slices, 198 g/g) of rye 
bread (Figure 10). A stepwise increase in the rye bread dose was applied to 
diminish abdominal discomfort, which is typical for suddenly introduced high 
doses of rye bread. After the habitual diet period, the subjects were instructed to 
exclude all other sources of rye, oat, barley, and whole-grain wheat in their diet 
until the end of the trial. In their place, all subjects were provided with suitable 
cereal food items based on refined wheat, rice, and corn. At the end of each 
dietary period, fasting blood samples were drawn before moving on to the next 
dietary period. 
 
Figure 10. Study design for the 6-week dietary intervention (Studies III and IV). Arrows indicate 
collection of overnight fasting blood samples. Modified from Study IV. 
Sixty-eight healthy volunteers were recruited for the dietary intervention. The 
volunteers were given written and oral information about the trial in advance, 
after which they completed an eligibility questionnaire and attended a blood 
screening test. Exclusion criteria included hemoglobin < 125 g/L for females or 
< 135 g/L for males, serum TC > 6.5 mmol/L or TG > 4.0 mmol/L, medication 
affecting serum lipids or gastrointestinal function, and use of antibiotics within 
the past three months, which might interfere with intestinal absorption by 
Habitual diet 
1 week 
   
 
 
Baseline 
1 week 
 Rye bread without added plant sterols         
3 slices (99 g/d) 6 slices (198 g/d) 
 2 weeks  2 weeks  
 
 
Rye bread enriched with plant sterols     
3 slices (99 g/d) 6 slices (198 g/d) 
 2 weeks  2 weeks  
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altering gut microbiota. Additionally, the use of vitamin/fish oil supplements 
was forbidden from one month before to the end of the trial. The subjects were 
instructed to maintain their body weight, physical activity, and possible 
medication constant during the trial. All subjects signed an informed consent. 
The study protocol was approved by the Ethics Committee of Helsinki 
University Central Hospital, Helsinki, Finland, and is registered in 
www.ClinicalTrials.gov under the study ID no. NCT01084226. 
The subjects were randomly allocated into two equal groups according to TC 
concentration and gender. The subjects in the PS group were provided with rye 
bread enriched with PSs, while the other half of the subjects received identical 
rye bread but without added PSs (control) in a double-blinded manner. The 
dose of the added PSs was 2 g/d during the first two weeks of the rye bread 
period and 4 g/d during the second two weeks of the rye bread period. 
All subjects were instructed to keep dietary records during the last three days 
of each dietary period. In addition, the amount and type of cereal foods were 
documented daily.  
Of the 68 subjects, three dropped out for personal reason or because of or 
time schedule conflicts. Moreover, one subject was excluded after the trial for 
not returning the food diary and for also reporting not having consumed the rye 
bread during the trial. Another subject was excluded for changing her hormonal 
medication during the trial. Ultimately, the data from 63 subjects were included 
in the statistical analyses (see Table 6 for demographic characteristics). 
Table 6. Demographic characteristics of the study subjects participating in the dietary 
intervention. Values are presented as mean (±SD). Modified from Studies III and IV. 
Variable All PS group Control group 
n 63 32 31 
Gender (females/males) 47/16 24/8 23/8 
Age (y) 35.8 (12) 34.6 (11.7) 37.1 (12.4) 
Weight (kg) 68.8 (13.6) 67.8 (13.5) 69.8 (13.8) 
BMI 24.1 (3.2) 24.0 (3.3) 24.1 (3.2) 
Total cholesterol (mmol/L) 5.07 (0.85) 5.06 (0.77) 5.08 (0.94) 
LDL cholesterol (mmol/L) 3.09 (0.74) 3.07 (0.75) 3.11 (0.75) 
HDL cholesterol (mmol/L) 1.63 (0.46) 1.63 (0.48) 1.63 (0.45) 
Triacylglycerols (mmol/L) 1.13 (0.51) 1.17 (0.53) 1.08 (0.48) 
Total energy intake (MJ)  7.84 (1.86) 7.83 (1.70) 7.85 (2.04) 
Cereal fiber intake (g/d) 11.70 (4.17) 11.66 (4.64) 11.74 (3.70) 
 
In the investigation of the effect of rye bread intake on the oxidation resistance 
of isolated LDL particles (Study III), the subjects served as their own controls, 
as the oxidation resistance of LDL after the second rye period was compared 
with that obtained at baseline (with null rye intake). In the evaluation of the 
suitability of rye bread to function as a food carrier for added PSs (Study IV), the 
decrease in plasma lipids and serum apolipoproteins (TC, LDL-C, apoB/apoA1, 
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and TC/HDL-C ratios) within the PS group was compared with that of the 
control group. 
4.2 MATERIALS 
4.2.1 RYE BREADS 
Two kinds of rye breads were used in the study. For the PS group in the dietary 
intervention, a rye bread enriched with PSs [150] (‘Ruisihme’, Fazer Bakeries, 
Lahti, Finland) was used. The bread was sourdough-processed and yeast-
leavened and consisted of whole-grain rye (68.3%), rye bran (8.3%), water, 
refined wheat flour (20%), added PSs, barley and rye malt extract, mineral salt, 
magnesium sulfate, potassium chloride, and yeast. All ingredients are reported 
on a dry weight basis. The fiber and alkylresorcinol contents of the bread were 
9.4 g/100 g and 50.5 mg/100 g, respectively, and the amount of the added PSs 
was 2.0 g/100 g (on a wet weight basis). For the control group of the dietary 
intervention trial, an identical rye bread without PS enrichment was specially 
baked by the same bakery. In the kinetic study, the latter rye bread was solely 
used. 
4.2.2 SOLVENTS, REAGENTS, AND CHROMATOGRAPHIC EQUIPMENT 
Acetonitrile, hexane, and methanol (MeOH) were obtained from Rathburn 
Chemicals Ltd. (Walkenburg, Scotland, UK) and ortho-phosphoric acid from 
Riedel-de Haën (Seelze, Germany). Silanizing agents trimethylchlorosilane and 
hexamethyldisilazane were from Pierce (Rockford, IL, USA) and pyridine from 
Romil (Waterbeach, Cambridge, UK). Acetic acid, diethylether, sodium acetate, 
potassium dihydrogen phosphate, ascorbic acid, and copper sulfate were 
obtained from Merck GmbH (Darmstadt, Germany) and β-glucuronidase from 
Roche Diagnostics GmbH (Mannheim, Germany). Ethylenediaminetetraacetic 
acid (EDTA) and sulfatase were from Sigma-Aldrich Co. (St. Louis, MO, USA), 
and ethanol was from Altia Oyj (Rajamäki, Finland). Commercial kits (Konelab 
60i) for the determination of serum lipids and apolipoproteins were from 
Thermo Scientific Oy (Vantaa, Finland). DEAE-Sephadex and sephadex G-25 
column were obtained from Pharmacia Biotech, (Uppsala, Sweden). BP-1 and 
BP-5 columns were from SGE (SGE Analytical Science Pty Ltd., Ringwood, 
Victoria, Australia). Inertsil ODS-3 column was from GL Sciences Inc. (Tokyo, 
Japan) and Quick Release RP-18 column from Upchurch Scientific Inc. (Oak 
Harbor, WA, USA). 
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4.2.3 STANDARDS 
Standards for alkylresorcinols C15:0, C17:0, C19:0, C21:0, and C23:0 were 
kindly provided by Professor Kristiina Wähälä, or purchased from ReseaChem 
Life Science (Burgdorf, Switzerland). The internal standard: alkylresorcinol 
C20:0 was purchased from Dr. Nawaf Al-Maharik, University of St. Andrews 
(St. Andrews, UK). The standard for DHPPA was from Aldrich (Steinheim, 
Germany) and for DHBA from IsoSep AB (Tollinge, Sweden). Syringic acid (Syr 
A) was from Sigma-Aldrich Co. (St. Louis, MO, USA). 
4.2.4 INSTRUMENTATION 
Ultracentrifugation for separating the lipoprotein fractions was performed with 
a Beckman Optima LE-80K ultracentrifuge with a Ti 50.4 rotor.  
The analytical instruments used for the commercial kits for serum/plasma 
lipid and apolipoprotein determination were by Thermo Scientific (Vantaa, 
Finland).  
Alkylresorcinols were quantified with gas chromatography-mass 
spectrometry (GC-MS) (Fisons Instruments, Manchester, UK), consisting of a 
GC 8000 gas chromatograph and an MD 1000 quadrupole mass spectrometer.  
DHPPA and DHBA were analyzed using a high-performance liquid 
chromatography (HPLC) system by ESA Biosciences, Inc. (Chelmsford, MA, 
USA) equipped with a model 540 autosampler, two model 580 solvent pumps, 
and a model 5600 coulometric electrode array detector (CEAD) with eight 
electrode pairs.  
The oxidation resistance of LDL was monitored by UV-spectrophotometer 
(Safire Scientific, India) with Magellan data analysis software (TECAN, Austria 
GmbH). 
4.3 METHODS 
4.3.1 SAMPLE COLLECTION 
4.3.1.1 Kinetic study (Studies I and II) 
For the blood sampling, a catheter was placed in the cubital vein to avoid 
numerous needle punctures (altogether 12). All blood samples were drawn in 
EDTA-coated tubes, cooled to room temperature, centrifuged, and plasma was 
stored at -20°C until analysis. The subjects collected all urine at the same time-
points as blood samples were drawn. Additionally, between the time-points 16 
and 24 h the subjects were advised to collect all urine in a container. The 
volumes of the urine samples were measured, and 10 ml of each sample was 
stored at -20°C until analysis. 
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4.3.1.2 Dietary intervention (Studies III and IV) 
Blood samples were collected by venipuncture after overnight fasting. Samples 
were drawn in either EDTA-coated tubes or serum tubes and set aside to cool to 
room temperature. Samples were then centrifuged to separate plasma and 
erythrocytes before deep-freezing (-80°C) or further treatment on the same day. 
The subjects collected overnight (12 h) urine in a container (containing 2 g of 
ascorbic acid), on the last night of the baseline period as well as during the 
second two-week rye period. Urine volumes were measured and a 10-mL sample 
was stored at -20°C until analysis. 
4.3.2 ISOLATION OF LIPOPROTEINS AND DETERMINATION OF LIPIDS 
Plasma lipoprotein fractions were isolated by sequential ultracentrifugation 
[151]. The density for very low-density lipoprotein (VLDL) was 1.006 g/mL, the 
range for LDL 1.019 – 1.063 g/mL, and the range for HDL 1.063 – 1.21 g/mL. 
Cholesterol and TG concentrations in the lipoprotein fractions were determined 
by enzymatic methods using commercial kits. 
4.3.3 DETERMINATION OF SERUM APOLIPOPROTEINS 
Serum concentrations of apoB and apoA1 were determined by 
immunoturbidometric methods using commercial kits. 
4.3.4 QUANTITATIVE ANALYSIS OF ALKYLRESORCINOL METABOLITES 
IN SERUM/PLASMA 
Plasma (100 µL) together with 20 ng of the internal standard SyrA in 2 µL of 
MeOH were hydrolyzed overnight at 37˚C with a hydrolysis solution (0.1 mol/L 
Na-acetate buffer pH 5, 2 U/mL sulfatase, and 0.2 U/mL β-glucuronidase). 
Thereafter, the sample was acidified (pH 3) using 10 µL of glacial acetic acid and 
extracted with 2 mL of diethylether by vigorously shaking for 2 min. The organic 
phase was collected and extraction repeated three times. The organic phases 
were combined, evaporated to dryness under nitrogen, and resuspended with 50 
µL of MeOH and 100 µL of HPLC mobile phase (20% phase B / 80% phase A). 
The mobile phases consisted of 50 mM phosphate buffer (pH 2.3) - MeOH 
(90:10, v/v) (phase A) and 50 mM phosphate buffer (pH 2.3) - MeOH - 
acetonitrile (40:40:20, by volume) (phase B).  The sample was filtered through a 
Gelman GHP 0.2-µm filter, and 10 µL was analyzed with HPLC-CEAD. For the 
analysis, we used a 25-min linear gradient from 0 to 100% phase B, thereafter 12 
min 100% phase B, followed by re-equilibration of the column with 0% phase B 
for 15 min, with a total flow of 0.3 mL/min. The analytical column was an 
Inertsil ODS-3, 3 x 150 mm with particle size 3 µm, connected to a Quick 
Release RP-18, 3 x 10 mm guard column. DHPPA was quantified at 570 mV, 
DHBA at 670 mV, and syringic acid at 380 mV. 
Materials and methods 
42 
4.3.5 QUANTITATIVE ANALYSIS OF ALKYLRESORCINOL METABOLITES 
IN URINE 
A 25-µL sample of the urine together with 25 µL of hydrolysis solution (0.1 mM-
sodium acetate buffer (pH 5), 2 U/mL sulfatase, and 0.2 U/mL β-glucuronidase) 
were incubated overnight at 37˚C. Thereafter, 318.5 ng of the internal standard, 
SyrA (in 50 µL of MeOH and 650 µL of HPLC mobile phase (20% phase B / 80% 
phase A, for compositions, see Section 4.3.4.), was added, and 10 µL was 
analyzed with HPLC-CEAD as described above (see Section 4.3.4.). 
4.3.6 OXIDATION OF LDL AND HDL 
The oxidation resistance of isolated LDL and HDL against copper-induced 
oxidation was determined using the method by Esterbauer [112]. The 
lipoprotein fractions were first purified from EDTA using Sephadex G-25 gel 
filtration, column 1 x 20 cm. EDTA-free LDL or HDL in a concentration of 100 
μg protein/mL, in 0.01 M phosphate-buffered saline was exposed to 1.66 μM of 
freshly prepared copper sulfate (CuSO4) to initiate oxidation of PUFAs in LDL 
or HDL. The subsequent formation of conjugated dienes was monitored by UV-
spectrophotometer at 234 nm wavelength at room temperature every 3 min for 
10 h. The lag time – occurring prior to the formation of the conjugated dienes 
(propagation phase) – was defined graphically as the time (min) to the intercept 
of the tangents of the baseline and propagation phase. The slope of the 
propagation tangent was defined as the velocity of the conjugated diene 
production (nmol dienes/min mg LDL or HDL protein). 
4.3.7 QUANTITATIVE ANALYSIS OF ALKYLRESORCINOLS IN RYE 
BREADS 
The rye breads used in the study were analyzed for their alkylresorcinol contents 
using a method reported by Ross [34], with slight modifications. Briefly, bread 
samples were dried and homogenized and thereafter 25 mg was extracted three 
times with 2 mL of fresh 1-propanol - water (10 mL, 3:1 v/v) on a heating block 
(2 x 2 h and 1 x 1 h). The combined extracts were evaporated to dryness and 
reconstituted with 1 mL of ethyl acetate. To 20 µL of the sample, 50 µL of the 
internal standard, alkylresorcinol C20:0, was added (97.5 ng/mL) and 
thereafter evaporated to dryness. The silanizing agent (100 µL) 
(trimethylchlorosilane - hexamethyldisilazane - pyridine 9/3/1 by volume) was 
added, and the samples were analyzed by GC-MS [45], with slight modifications. 
For the separation and quantification, we used a BP-1 capillary column. The 
temperature program was as follows: starting with 150˚C for 1 min, increasing 
by 40°C/min to 230°C, then increasing by 9°C/min to 300°C, holding for 15 
min. The temperatures of the injector and interface heating were 300˚C and 
250˚C, respectively. The flow rate was 1 mL/min.  
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4.3.8 QUANTITATIVE ANALYSIS OF ALKYLRESORCINOLS IN LDL 
FRACTION 
Alkylresorcinols in LDL were quantified using a modification of a plasma 
method described by Linko et al. [19, 71]. Briefly, to 500 µL of LDL, 39 ng of the 
internal standard, alkylresorcinol C20:0, in 20 µL of MeOH, and 500 µL of 
water were added and incubated at 37°C overnight. After incubation, the sample 
was allowed to cool to room temperature and extracted four times with 4 mL of 
diethylether. The organic phases were combined and evaporated to dryness. The 
sample was reconstituted with 300 µL of MeOH and thereafter purified using 
DEAE-Sephadex in free base form. The gel was packed in MeOH in a 0.5 x 1.5 
cm column, the sample applied to the column in 300 µL of MeOH, and the tube 
rinsed with 300 µL of MeOH, then again applied to the column. The column was 
first eluted with 6 mL of MeOH and discarded. Alkylresorcinols were eluted 
further with 6 mL of 0.1 M acetic acid in MeOH. This fraction was evaporated to 
dryness and the sample was derivatized by incubating for 30 min at room 
temperature with 100 µL of silanizing agent pyridine - hexamethyldisilazane - 
trimethylchlorsilane 9:3:1 (vol/vol/vol), and then analyzed by GC-MS. The 
column was a 12.5 m BP-1 with film thickness of 0.25 µm and internal diameter 
of 0.22 mm. Injection volume of the sample was 1 µL. The carrier gas was 
helium and the flow rate 1 mL/min. The column temperature was set to 150˚C 
for 1 min, then raised by 40˚C/min to 230˚C, followed by an increase of 
9˚C/min to 290˚C, kept for 2 min, then increased further by 12˚C/min to 
300˚C and kept for 13 min. The injector temperature was 280˚C and that of the 
ion source 250˚C. Ionization energy was 70 eV. Differing from the method by 
Linko et al. [19], we used ion m/z 268 for quantifying alkylresorcinols. 
4.3.9 QUANTITATIVE ANALYSIS OF LIPOPHILIC (PRO)VITAMINS IN 
SERUM 
The analysis of α- and γ-tocopherols as well as α- and β-carotenes was 
performed by Professor Georg Alfthan at the National Institute of Health and 
Welfare, Helsinki, Finland. Briefly, 50 µL of serum sample was mixed with 800 
µL of 50% ethanolic solution containing ascorbic acid, butylated hydroxytoluol, 
echinenone (internal standard for carotenoids), and tocol (internal standard for 
tocopherols), followed by extraction with 1 mL of hexane. A 0.8-mL hexane 
aliquot was evaporated to dryness under nitrogen and resuspended with 120 μL 
of MeOH. For the separation of α- and γ-tocopherols, an Inertsil ODS-3 column 
(2.1 x 100 mm, with film thickness of 3 μm) was used. Injection volume of the 
sample was 5 µL. The mobile phase was MeOH and the flow rate 0.3 mL/min. 
The tocopherols were detected by their fluorescence at 292/324 nm using 
vitamin/tocol peak height ratios. For the separation of α- and β-carotenes, a 
NovaPak column (3.9 x 150 mm, with film thickness of 4 μm) was used. 
Injection volume of the sample was 25 µL. The mobile phase was acetonitrile - 
dichlormethane - MeOH (7:2:1, by volume) and the flow rate 1.2 mL/min. The 
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carotenoids were detected at 450 nm using carotenoid/echinenone peak height 
ratios. 
4.3.10 ANALYSIS OF DIETARY INTAKE OF NUTRIENTS 
The dietary data were analyzed using Diet32 software, version 1.4.4.2., by Aivo 
Finland Oy (Turku, Finland), which is based on the food composition database 
(Fineli) of the National Institute of Health and Welfare (Helsinki, Finland). 
4.3.11 PHARMACOKINETIC ANALYSIS OF DHPPA AND DHBA 
The kinetic parameters were calculated by Dr. Johan Lundin at the Institute for 
Molecular Medicine Finland, Helsinki, Finland. The parameters for DHPPA and 
DHBA were maximum plasma concentration (Cmax), maximum urinary 
excretion rate (µmol/h)(ERmax), time of reaching Cmax/ERmax (tmax), and t1/2, at 
which the plasma concentration/urinary excretion rate has decreased to half of 
Cmax/ERmax, and finally the area under the kinetic curve (AUC). Comparisons of 
the pharmacokinetic parameters between the two metabolites or between 
genders were carried out by independent or paired t-tests. All pharmacokinetic 
analyses were conducted using STATA software (version 10.0 StataCorp, College 
Station, TX, USA). 
4.3.12 STATISTICAL ANALYSIS 
The data obtained in the dietary intervention trial were tested for normality of 
distribution using the Kolmogorov-Smirnov test.  For normally distributed 
variables, paired t-test and independent t-test were used to uncover differences 
within and between groups, respectively. For non-normally distributed 
variables, Wilcoxon Signed-Rank test or Mann-Whitney U-test was performed. 
Correlation analysis was conducted using Spearman’s rho. All statistical 
analyses were conducted with SPSS for Windows, version 15.0 (SPSS, Chicago, 
IL, USA). P-values < 0.05 were considered significant. The results are presented 
as means (± SD) unless otherwise stated. 
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5 RESULTS 
5.1 PLASMA KINETICS OF ALKYLRESORCINOL 
METABOLITES (STUDY I) 
We determined plasma DHPPA and DHBA concentrations (nmol/L) after a two-
day low-alkylresorcinol diet and overnight fasting (0 h), and thereafter following 
the intake of a single dose of rye bread containing 100 mg (257.6 µmol) of 
alkylresorcinols, at 11 time-points (3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 25 h), using 
HPLC-CEAD. Based on the resulting concentrations, pharmacokinetic 
parameters were calculated and statistical analyses conducted (n = 15). The 
kinetic curves are drawn according to the mean plasma concentrations of 
DHPPA and DHBA at each sampling time-point, thus only illustrating the 
average appearance of these metabolites in the circulation (Figure 11).  
 
 
 
Figure 11. Mean (± SEM) plasma concentrations of alkylresorcinol metabolites DHPPA and DHBA 
in 15 individuals before (0 h) and 3 - 25 h after the intake of a single dose of rye bread 
containing 100 mg (257.6 µmol) of alkylresorcinols. Modified from Study I. 
The pharmacokinetic calculations are based on individual parameters (Cmax, 
tmax, t1/2, and AUC). According to these calculations, Cmax was 350.5 (± 29.7) 
nmol/L for DHPPA vs. 570.3 (± 45.7) nmol/L for DHBA, (P < 0.0001). Despite 
these differences, the respective tmax values were rather similar, 6.4 (± 0.7) and 
6.1 (± 0.5) h for DHPPA and DHBA, respectively. Furthermore, a significant (P 
= 0.0002) difference was present in t1/2 between DHPPA and DHBA, 16.3 (± 1.8) 
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and 10.1 (± 0.8) h, respectively. At 25 h, both metabolites appeared in 
significantly higher concentrations than at 0 h (P = 0.001 for both), suggesting 
that the elimination from the circulation was not yet completed. Finally, AUC 
also differed significantly (P < 0.0001) between DHPPA [4269 (± 244) nmol · 
h/L] and DHBA [6631 (± 389) nmol · h/L].  
Plasma concentrations and AUCs were significantly higher in females than in 
males for both metabolites (P = 0.01 for DHPPA and p = 0.03 for DHBA), 
although all subjects received an equal dose of alkylresorcinols (Figure 12). 
However, when adjusted for body weight, the difference disappeared (data not 
shown). Based on this, we speculated that the metabolic rate is quite similar for 
both genders, but due to the smaller body weight (and thus, blood volume) of 
females, their postprandial plasma concentrations appear higher, even though 
the total amount of the metabolites is quite similar in all subjects. 
 
 
 
Figure 12. Mean plasma concentrations of alkylresorcinol metabolites DHPPA and DHBA in 8 
females and 7 males before (0 h) and 3 - 25 h after the intake of a single dose of rye 
bread containing 100 mg (257.6 µmol) of alkylresorcinols. Values are not adjusted for 
body weight. 
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5.2 URINARY KINETICS OF ALKYLRESORCINOL 
METABOLITES (STUDY II) 
DHPPA and DHBA were determined in urine samples collected after a two-day 
low-alkylresorcinol diet and overnight fasting (0 h), and thereafter following the 
intake of a single dose of rye bread containing 100 mg (257.6 µmol) of 
alkylresorcinols at 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 25 h. Furthermore, an 
overnight (16-24 h) urine sample was collected in a container. The analysis was 
performed using HPLC-CEAD. The obtained values at each time-point were first 
corrected by the respective urine volumes and then divided by the number of 
hours elapsed since the previous collection time-point. The results are presented 
as urinary excretion rates (ERs) per hour. The kinetic curves of the mean ER of 
DHPPA and DHBA at each collection time-point are shown in Figure 13.  
 
 
Figure 13. Mean (± SEM) urinary excretion of alkylresorcinol metabolites DHPPA and DHBA in 15 
individuals before (at 0 h) and at 3 - 25 h after ingestion a single dose of rye bread 
containing100 mg (257.6 µmol) of alkylresorcinols. Modified from Study II. 
According to the pharmacokinetic calculations, ERmax for DHPPA was 8.15 
µmol/h and for DHBA 4.46 µmol/h (P < 0.0001). However, these distinct ERmax 
values were reached fairly simultaneously, tmax being 5.40 h for DHPPA and 
6.00 h for DHBA (P = 0.167). The respective t1/2 values for these metabolites 
were 11.89 and 9.93 h (P = 0.142, n = 12). Three subjects generated multiple 
peaks, and therefore, the t1/2 could not be determined for them. At 25 h, the ERs 
for DHPPA and DHBA were still significantly greater than those at 0 h (P = 
0.001 for both), indicating an incomplete elimination of these metabolites. The 
AUC for DHPPA was 67.3 µmol/25 h, which accounts for 26.1% of recovery from 
the ingested dose of alkylresorcinols (257.6 µmol). This is significantly higher (P 
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< 0.0001) than the AUC for DHBA, 44.7 µmol/25 h, which accounts for 17.3% of 
recovery. The total (DHPPA + DHBA) mean urinary recovery was 43.4% of the 
ingested dose of alkylresorcinols over 25 h. Females and males did not differ 
significantly in any of the pharmacokinetic parameters (P > 0.168 for all). 
5.3 OXIDATION RESISTANCE OF LDL (STUDY III) 
In the dietary intervention, we determined the oxidation resistance of isolated 
LDL particles [112] at baseline (0 g/d of rye intake) and at the end of the second 
two-week rye period (6 slices, 198 g/d of rye bread). The main outcomes were 
the duration of lag time and the slope of the propagation phase. We observed a 
significant prolongation in lag time (14.4%, P < 0.001) as well as a decrease in 
the slope of the propagation phase (4.5%, P = 0.048) from baseline to the end of 
the rye period (Figure 14). The observed prolongation in lag time did not differ 
significantly between subjects who did or did not receive added PSs in rye bread 
(P = 0.429), nor did the decrease in the slope of the propagation phase (P = 
0.261). 
 
 
Figure 14. Oxidation resistance of isolated LDL particles was determined according to the 
Esterbauer method [112] at baseline (with no rye intake) and following the second two-
week rye period (with 198 g/d of rye bread intake) in 63 healthy subjects. The curves 
illustrate mean absorbance at 234 nm as a function of time (min). Modified from Study 
III. 
Concurrently, the concentration of alkylresorcinols in the LDL fraction (nmol/L 
plasma) was increased by 8-fold, (P < 0.001), but we were unable to show any 
correlation between oxidation lag time and alkylresorcinols (P = 0.407 for total 
alkylresorcinols, P = 0.294 – 0.546 for the separate alkylresorcinol homologs). 
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The slope of the propagation phase did not correlate with either total 
alkylresorcinols or separate homologs (P = 0.950 for total alkylresorcinols, P = 
0.188 – 0.960 for the separate alkylresorcinol homologs). The concentrations of 
the alkylresorcinol homologs in LDL samples of the study subjects at baseline 
and at the end of the second two-week rye period are shown in Figure 15. 
 
 
Figure 15. Concentrations of the alkylresorcinol homologs C15:0 - C25:0 in LDL samples of study 
subjects at baseline and at the end of the second two-week rye period (with 198 g/d of 
rye bread intake). 
The serum concentrations of lipophilic (pro)vitamins did not change from 
baseline to the end of the second two-week rye period (P > 0.14 for all). 
However, TC-adjusted α- and γ-tocopherols correlated positively with the lag 
time at baseline (r = 0.287, P = 0.024, and r = 0.400, P = 0.001, respectively) 
and following the rye period (r = 0.329, P = 0.012, and r = 0.456, P < 0.001, 
respectively).  
We observed no significant change in the oxidation resistance (lag time) of 
HDL (P = 0.319) from baseline to the end of the second two-week rye period.  
Table 7 summarizes the results observed in the oxidation study. 
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Table 7. Summary of results of the LDL oxidation resistance study (III). 
Determined values Baseline Rye period 
Lag time in LDL oxidation assay (min) 192.0 219.1 * 
Slope of propagation phase in LDL oxidation assay 
(nmol dienes/min mg LDL protein) 
 
1.62 
 
1.55 ** 
Alkylresorcinol intake from rye bread (mg/d) 0 97.9 * 
Alkylresorcinol concentration in LDL (nmol/L plasma) 6.1 48.0 * 
Serum concentration of α-tocopherol (µmol/L) 22.6 22.8 
Serum concentration of γ-tocopherol (µmol/L) 2.02 1.89 
Serum concentration of α-carotene (µmol/L) 0.44 0.43 
Serum concentration of β-carotene (µmol/L) 0.76 0.75 
Lag time in HDL oxidation assay (min) 73.9 71.9 
* P < 0.001 compared with baseline 
** P < 0.05 compared with baseline  
5.4 PLANT STEROLS AND PLASMA CHOLESTEROL 
(STUDY IV) 
In this part of the dietary intervention, we evaluated the suitability of rye bread 
to act as a food carrier for added PSs by measuring plasma lipids and serum 
apolipoproteins in 63 healthy subjects. The subjects in the PS group (n = 32) 
received 2 g/d of added PSs in the rye bread during the first two-week rye 
period. The dose was doubled for the second two-week rye period. The control 
group (n = 31) received identical rye bread, but without the added PSs. The main 
outcomes were%-changes in LDL-C concentration and apoB/apoA1 ratio. 
During the first two weeks of the rye period (3 slices, 99 g/d of rye bread) 
LDL-C decreased by 8.1% (0.20 mmol/L) and apoB/apoA1 ratio by 8.3% in the 
PS group compared with controls, both differences being statistically significant 
(P = 0.021 and P = 0.006, respectively). Accordingly, at the end of the second 
two-week rye period with a doubled dose of rye bread (6 slices, 198 g/d), the 
reductions in the PS group were 10.4% (0.33 mmol/L) for LDL-C and 5.5% for 
the apoB/apoA1 ratio (P = 0.001 and P = 0.043, respectively) compared with 
controls (Figure 16). The reduction in the apoB/apoA1 ratio was due to a 
decrease in apoB (8.8% at 2 g/d of PSs and 5.9% at 4 g/d of PSs, compared with 
controls), while apoA1 remained stable. In the PS group, also TC and TC/HDL-C 
ratio were reduced following the first two-week rye period (5.1%, P = 0.026, and 
7.2%, P = 0.015, respectively), and TC was diminished further during the second 
two-week rye period (6.5%, P = 0.002) compared with controls. No changes 
occurred in the HDL-C, VLDL-C, TG, α- and γ-tocopherol, or α- and β-carotene 
concentrations in study subjects from baseline to the end of the second two-
week rye period.  
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Figure 16. Percentage changes of plasma LDL-C concentration and serum apoB/apoA1 ratio for 
the PS (n=32) and control (n=31) groups from baseline to the end of the first two-week 
rye period with 99 g/d of rye bread intake (containing 2 g/d of added PSs for the PS 
group), and to the end of the second two-week rye period with 198 g/d of rye bread 
intake (containing 4 g/d of added PSs for the PS group). All %-changes in the PS group 
differ significantly from those in the control group (P < 0.05). Furthermore, within the PS 
group, the reductions in LDL-C and apoB/apoA1 ratio from baseline to the end of the 
second rye period (198 g/d of rye bread with 4 g/d of PSs) were significant (P < 0.05). 
Modified from Study IV. 
Besides documentation in three-day food diaries, we monitored subjects' 
treatment compliance (intake of rye bread) by determining plasma DHBA 
concentration (Figure 17). DHBA was chosen as a biomarker rather than 
DHPPA because it produces higher plasma concentrations. In general, dietary 
compliance was good and plasma DHBA levels increased following the larger rye 
bread dose. Furthermore, we observed that plasma DHBA concentration during 
the first two-week rye period was similar to that in the habitual diet (data not 
shown), suggesting that Finns commonly consume relatively large amounts of 
whole-grain rye/wheat foods.  
 
-8
-6
-4
-2
0
2
4
6
8
baseline 99 g/d of rye
bread
198 g/d of rye
bread
  %
-c
h
an
ge
 
Dietary period 
ApoB/apoA1,
control
group
LDL-C,
control
group
ApoB/apoA1,
PS group
LDL-C,
PS group
Results 
52 
 
Figure 17. Plasma concentrations of the alkylresorcinol metabolite DHBA, utilized as a biomarker 
for rye bread intake, at baseline (0 g/d of rye bread intake), after the first two-week rye 
period with 99 g/d of rye bread intake, and after the second two-week rye period with 
198 g/d of rye bread intake (n = 63). In the boxplot presentation, the length of the box is 
the variable's interquartile range, containing 50% of the scores. The whiskers extend to 
the variables' smallest and largest values, except for the outliers, which are indicated 
with circles and an asterisk. The horizontal line inside the box indicates the median 
value. Modified from Study IV. 
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6 DISCUSSION 
6.1 KINETIC STUDY OF ALKYLRESORCINOL 
METABOLITES (STUDIES I AND II) 
The kinetic parameters of DHPPA and DHBA are determined here for the first 
time. These data are of importance in characterizing the biomarker properties of 
these compounds concerning whole-grain rye intake. Even though we observed 
a relatively large interindividual variation in the kinetic parameters, the data 
indicate that both metabolites possess good biomarker potential in both plasma 
and urine.  
The study subjects had been instructed to avoid whole-grain rye-, and wheat-
containing foods for two days before entering the study. At baseline, we 
observed very low plasma and urinary concentrations of DHPPA and DHBA, 
indicating that the two-day wash-out period was both successful and sufficient. 
Thereafter, ingestion of the single dose of rye bread triggered a rapid increase in 
the metabolite concentrations, indicating efficient metabolism and excretion of 
alkylresorcinols. We observed DHPPA both peaking and possessing t1/2 first in 
urine and later in plasma, while DHBA peaked simultaneously in plasma and 
urine and also had a similar t1/2 in both body fluids. DHPPA peaking earlier in 
urine than in plasma could presumably be explained by its higher 
glucuronidization rate (39%) than that for DHBA (18%), as reported recently 
[81]. The hepatic glucuronidization increases the water solubility of DHPPA, 
thereafter becoming quickly filtrated into urine by the kidneys.   
The sampling of blood was interrupted for the night while the collection of 
urine samples was continued overnight using a container. The lower urinary ER 
discovered in the overnight urine collection (compared with the preceding or the 
following ones) suggests a slight slow-down of alkylresorcinol 
metabolism/excretion while sleeping. The samplings were finished on the 
following morning at 25 h, after over-night fasting. At this time-point, the final 
plasma concentrations and urinary ER for the metabolites were still significantly 
higher than the corresponding baseline values, indicating that even these single 
samples could potentially distinguish whether whole-grain rye has been 
consumed by the subject. On the other hand, at 25 h the kinetic curves indicated 
that the metabolism of the given dose of alkylresorcinols (Figure 11) and the 
urinary excretion of the formed metabolites (Figure 13) were almost completed. 
This observation is also supported by calculations according to which the 
urinary excretion of DHPPA and DHBA during the last hour accounted for only 
about 2.5% of the total AUC0-25 h.  
The total AUC0-25h of the urinary metabolites was also used to calculate 
recovery, which was altogether 43% of the ingested amount of alkylresorcinols. 
This is in line with the literature, as the urinary recovery of DHPPA and DHBA 
was quite recently reported to be 45% after 132 mg/d intake of alkylresorcinols 
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[70]. The recovery calculations are also supported by the reported absorption of 
alkylresorcinols, which is around 60% of the ingested amount [69]. 
Additionally, according to a recent study, it is also possible that a small 
proportion of the ingested alkylresorcinols has been stored in adipose tissue, 
therefore escaping detection [75]. The possibility of intact alkylresorcinols being 
delayed in the circulation as such is minor, as the kinetic data of alkylresorcinols 
have also described low plasma concentrations at 24 h after ingestion, and 
furthermore, estimated that AUC24-∞ would not exceed 10% of the AUC0-∞ [68]. 
Hence, we considered that the 25-h study period was sufficient. 
Females possessed higher plasma concentrations of DHPPA and DHBA than 
males, presumably due to their smaller body weight (and blood volume). We 
therefore adjusted the values for body weight. However, as the plasma 
concentrations of these candidate biomarkers cannot be used for estimating 
dietary intake (serving size) of whole-grain rye/wheat, it remains unclear 
whether this kind of correction is essential. 
Research among whole-grain cereals or cereal fiber is likely to increase since 
these food items show health-protecting effects, although the mechanisms have 
remained partly unclear. Presumably, also remaining samples from previous 
studies can be explored and relations between whole-grain/fiber exposure and 
incidence of certain diseases can be analyzed post hoc. Dietary data may not be 
available for samples or it may have become distorted by identification and 
quantification problems concerning whole-grain intake. In these cases, a 
reliable biomarker is a valuable tool. Alternatively, these candidate biomarkers 
can also be utilized in whole-grain rye-based dietary trials when monitoring 
treatment compliance. With the data here, we provide support for the use of 
plasma or urinary DHPPA and DHBA as biomarkers for the intake of whole-
grain rye. Plasma DHBA appeared in higher concentrations than DHPPA, but it 
is worth noting that the dose of alkylresorcinols can play a role in the 
proportional distribution of these metabolites and a definitive recommendation 
for the choice of either metabolite as a plasma biomarker of whole-grain rye 
intake cannot yet be made. However, in urine samples, DHPPA appeared a more 
promising choice because it had higher concentrations over the whole 25-h 
period. 
 Here, we analyzed DHPPA and DHBA using the methods developed in our 
laboratory [79, 102]. The methods are fast and simple to conduct and are also 
routinely performed in our laboratory. Compared with a method for 
alkylresorcinols [19], fewer steps are required. In addition, higher plasma 
concentrations of DHPPA and DHBA have been reported than those of 
alkylresorcinols in the same samples [92, 99]. This can be due to the longer t1/2 
for the metabolites and be an advantage when analyzing samples from subjects 
with low whole-grain rye/wheat intakes. 
Taken together, the present kinetic data indicate that DHPPA and DHBA in 
both plasma and urine samples possess good biomarker properties concerning 
whole-grain rye intake. Firstly, a two-day elimination of whole-grain rye/wheat 
foods from the diet reduced the quantified amounts effectively. Secondly, these 
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compounds responded rapidly to the ingestion of rye bread, and even at 25 h the 
levels were significantly higher than at baseline. Finally, after adjusting the 
plasma concentrations for body weight, no gender differences were present in 
the pharmacokinetic parameters. 
6.2 OXIDATION RESISTANCE OF LDL (STUDY III) 
The dietary intervention (Study III) reports a significant increase in the 
oxidation resistance of LDL from baseline (0 g/d of rye bread) to the end of the 
second two-week rye period (6 slices, 198 g/d of rye bread intake). The 
improved oxidation resistance was defined by significantly prolonged lag time as 
well as by reduced oxidation rate in the Esterbauer assay [112]. Additionally, rye 
bread consumption induced a significant increase in the LDL alkylresorcinol 
concentration, and particularly the longer chain homologs C23:0 and C25:0 
were accumulated in LDL, which is in line with previous observations [72, 73]. 
This can be due to the increased lipophility of the longer chain alkylresorcinols, 
playing a role in the incorporation of alkylresorcinols into the biological 
membranes [125]. 
Before Study III, we presumed that alkylresorcinols would play a role as 
antioxidants in the LDL particles, somewhat similarly to α-tocopherols, the 
main antioxidants in LDL [113]. This idea was supported by several facts. 
Firstly, the structure of alkylresorcinols resembles that of α-tocopherols, and 
both compounds can be found in LDL, although the concentration of α-
tocopherols is considerable higher than that of alkylresorcinols. Secondly, 
according to a recent report, alkylresorcinols (C15:0 and C17:0) have been found 
to prolong the oxidation lag time in the Esterbauer assay when added directly to 
the LDL solution [116]. Finally, our own laboratory experiments confirmed the 
improvement of oxidation resistance of LDL by addition of C17:0 
alkylresorcinols to the assay system (data not shown). The results here, did not, 
however, support our hypothesis, as the increased LDL alkylresorcinol 
concentration did not correlate positively with the observed oxidation resistance 
of these particles. Rather, these results were in line with an earlier report 
indicating poor antioxidant activity for alkylresorcinols [118]. Despite the 
negative observation, we cannot totally exclude some role of alkylresorcinols in 
the oxidation resistance of LDL. Alkylresorcinols have been suggested to 
stabilize the bilayer membranes of erythrocytes by decreasing mobility of the 
phospholipids [108], but whether this could occur on the surface monolayer of 
LDL and affect the oxidation resistance of this particle is unknown. Another 
potential bioactivity for alkyresorcinols concerns their phenolic ring, which in 
theory could be involved in regenerating α-tocopherols, those being oxidized 
during the lag time in the Esterbauer assay [112]. An activity like this has been 
reported for a few other phenols [152]. Moreover, it is possible that other rye-
originating phenols or phytochemicals (or their metabolites in humans) are able 
to regenerate α-tocopherols or possess another kind of antioxidant activity. 
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We determined the oxidation resistance of isolated HDL particles [112] to 
evaluate whether these particles could affect the oxidation resistance of LDL. 
Because the oxidation lag time of HDL did not change significantly following rye 
bread intake, we assumed that HDL particles did not contribute to the increased 
oxidation resistance of LDL. Instead, we found moderate correlations between 
the oxidation lag time of LDL and both tocopherols (α- and γ) at baseline and at 
the end of the second two-week rye period, but because these vitamins remained 
stable during the trial, they are not likely to explain the significant 
improvement. 
The samples from the present dietary intervention (see Section 4.1.2.) were 
also used for Study IV (Plant sterols and plasma cholesterol). Therefore, half of 
the subjects received rye bread enriched with PSs, while the other half received 
rye bread without added PSs. No significant differences were observed in 
oxidation resistance of LDL between subjects who did and those who did not 
receive added PSs. 
The results from this trial are in contrast to a previous study reporting no 
improvements in the oxidation resistance of LDL after supplemented rye bran 
or purified wheat fiber intake compared with the habitual diet [153]. The reason 
for the lack of effect remained unknown, and furthermore, this study did not 
report or correlate the obtained results with alkylresorcinols. Noteworthy is, 
however, that differing from our method, EDTA was present in the oxidation 
assay [153], and EDTA has the potential to interfere with copper-induced LDL 
oxidation [110]. 
Overall, the present dietary intervention shows that rye bread intake (3 
slices, 99 g/d during two weeks + 6 slices, 198 g/d during two weeks), compared 
with baseline diet (0 g/d of rye), caused a significant improvement in the 
oxidation resistance of LDL. The LDL alkylresorcinol concentration increased 
significantly following rye bread intake, but was not associated with the 
oxidation resistance, suggesting that alkylresorcinols are not the major causative 
antioxidants behind this phenomenon. The oxidation resistance of HDL was not 
affected by rye bread consumption, suggesting that HDL is also not likely to play 
a role in the oxidation resistance of LDL. Although α- and γ-tocopherols 
correlated with the oxidation lag time of LDL at baseline, and also following the 
second two-week rye period, they are not likely to explain the significant 
improvement because their concentrations remained stable. Finally, we cannot 
exclude that alkylresorcinols are involved to some degree in mediating the 
beneficial effect of rye bread intake on the oxidation resistance of LDL, but it 
seems likely that some other phytochemical(s) in rye are also involved. 
6.3 PLANT STEROLS AND PLASMA CHOLESTEROL  
(STUDY IV) 
The dietary intervention trial (Study IV) demonstrates that intake of rye bread 
enriched with PSs (2 g/d during two weeks), compared with control rye bread 
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(without added PSs), significantly reduced several risk factors for CVD. 
Additional positive changes were induced in some risk factors by doubling the 
dose of PSs for the following two-week period.  
The subjects chosen for this trial were normocholesterolemic or mildly 
hypercholesterolemic, and therefore, the baseline LDL-C was relatively low 
(mean 3.1 mmol/L). For the evaluation of PS function, we also included risk 
factors besides lipids, such as the apoB/apoA1 ratio, which reflects a balance 
between pro-atherogenic and anti-atherogenic lipoproteins in circulation. This 
ratio has additionally been suggested to provide more predictive power than the 
conventional lipid risk factors, particularly in a population with relatively low 
LDL-C levels [154, 155].  
In our study, the PS group, relative to controls, showed significant reductions 
in TC, LDL-C, apoB/apoA1, and TC/HDL-C ratios. These results indicate that 
the PS treatment reduced several known risk factors for CVD, besides lipids also 
the pro-atherogenic lipoprotein apoB, without depleting the anti-atherogenic 
apoA1. We observed slight, albeit insignificant, increase in these risk factors in 
the control group during the intervention, but the reason for this remains 
unknown.  
To our knowledge, rye bread has not been used as a food carrier for PSs 
before, and therefore, the cholesterol-lowering efficacy of PSs in this novel food 
matrix was of specific interest. The ultimate 10.4% (0.33 mmol/L) reduction in 
LDL-C in our trial is in agreement with a recent meta-analysis [26] reporting a 
maximal mean LDL-C reduction of 8.3% (0.32 mmol/L) for PS treatment. This 
indicates that the action of PSs had not been diminished by the components of 
rye bread. In other words, rye bread turned out to be a suitable food carrier for 
PSs, and the incorporation of PSs into rye bread may further enhance the 
health-protecting effect of rye bread. 
PS or plant stanol treatments have been associated with potential reduction 
in serum carotenoids in some [31, 156], but not all [157, 158], studies. In the 
present trial we determined the serum concentrations of α- and γ-tocopherols as 
well as α- and β-carotenes at baseline and after the second two-week rye period 
(6 slices/d of rye bread containing 4 g/d of PSs for the PS group), and observed 
no changes in these values. 
In the present intervention (Studies III and IV), the recommended intakes of 
rye bread were o g/d (baseline), 3 slices/d (99 g/d), or 6 slices/d (198 g/d). 
Treatment compliance of study subjects was good. This was monitored by 
analyzing the three-day food records and also by determining plasma DHBA 
concentration as a biomarker for rye bread intake. We preferred to utilize DHBA 
over DHPPA because the former shows a higher plasma concentration according 
to the results of Study I. Furthermore, we observed that plasma DHBA 
concentrations after the two rye doses (99 g/d or 198 g/d) differed from each 
other more clearly than those of DHPPA. We noted that the plasma DHBA 
concentrations were in line with the rye bread intakes reported in the three-day 
food diaries, confirming that subjects had followed the given instructions. In 
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addition, we analyzed the overall nutrient intakes from the food diaries and 
observed these to be fairly stable throughout the trial, except for fiber.  
A limitation of the study is the relatively short PS treatment periods (two weeks 
each). Although we assume that a steady state of serum lipids was achieved 
before blood sampling, it remains unclear whether we would have observed 
further changes had the dietary periods been longer. On the other hand, based 
on another study using plant stanol treatment, the major reductions in serum 
lipids were seen on day 8, with no further reduction occurring between days 8 
and 15 [159]. Also, taking into account the fairly high doses of rye bread in our 
trial (99 and 198 g/d), we were concerned about potential drop-out rates if 
longer treatment periods had been applied. Another limitation of the study was 
that we did not synchronize the blood samplings with the day of the menstrual 
cycle in premenopausal women, which might have affected cholesterol levels in 
women [160]. 
In summary, in the present dietary intervention, study subjects received rye 
bread without (control) or with added PSs (2 - 4 g/d) during 2 + 2 weeks.  
Compared with controls, the PS group demonstrated a significant reduction in 
cardiovascular risk factors such as LDL-C, TC, apoB/apoA1, and TC/HDL-C 
ratios. The results indicate that rye bread is a suitable food carrier for PSs, not 
interfering with the beneficial action of these dietary supplements. Additionally, 
serum lipophilic (pro)vitamins were unaffected by PSs. Finally, we have 
introduced the utilization of plasma DHBA as a biomarker for treatment 
compliance (rye bread intake) and consider it to be a promising tool for future 
research. 
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7 CONCLUSIONS 
This thesis explores rye bran-associated alkylresorcinols and their metabolites 
in healthy humans. We aimed to evaluate the suitability of alkylresorcinol 
metabolites DHPPA and DHBA as biomarkers for whole-grain rye intake, and 
also the potential antioxidant activity and cholesterol-lowering effect of rye 
bread intake on plasma LDL. We presumed that the antioxidant activity would 
be induced by alkylresorcinols in rye bread, while the cholesterol-lowering effect 
was expected to be caused by PSs, which were incorporated in rye bread for half 
of the study subjects. All data presented here were obtained from a kinetic study 
(Studies I and II) and a dietary intervention (Studies III and IV) using rye bread 
as a source of alkylresorcinols. The conclusions are as follows: 
 
1) The kinetic parameters for DHPPA and DHBA in human plasma (Study I) 
and urine (Study II) support the suitability of these substances as biomarkers 
for whole-grain rye intake. Some gender differences were present in the plasma 
parameters, but these disappeared after adjusting for body weight. However, 
whether this adjustment is needed remains unclear. Despite the identical 
alkylresorcinol dose for all subjects, large interindividual variation in metabolite 
concentrations was observed. This suggests that quantitative estimations of 
ingested rye servings cannot be done accurately. Instead, DHPPA and DHBA 
can provide useful tools in epidemiological studies exploring the association 
between habitual intake of whole-grain rye and chronic diseases, even when 
dietary food records are not available. Ultimately, DHPPA and DHBA possess 
longer plasma t1/2 than alkylresorcinols, which could be an advantage when 
whole-grain intakes are low. 
 
2) Rye bread intake significantly improves in vitro oxidation resistance of LDL 
(Study III). In addition, a significant increase in the LDL alkylresorcinol 
concentration was observed following rye bread consumption, but it did not 
correlate with the oxidation resistance of LDL. The lack of correlation suggests 
that alkylresorcinols were not the major causative antioxidants, although we 
cannot exclude the possibility that alkylresorcinols contribute to the oxidation 
resistance of LDL in some way. Vitamin E (α- and γ-tocopherols) was associated 
with the oxidation resistance of LDL, but as the level of vitamin E remained 
stable throughout the trial, it does not explain the significant improvement in 
resistance. Further studies should be conducted to clarify which substances in 
rye were involved in the significant improvement in the oxidation resistance of 
LDL and what mechanism underlies this beneficial change. Of special interest 
would be to elucidate whether this improvement contributes to the known 
cardiovascular protection in vivo.  
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3) Rye bread enriched with PSs significantly lowers LDL-C and apoB/apoA1 
ratio, compared with control rye bread (Study IV). The observed reduction in 
LDL-C is consistent with results in other PS trials, indicating that the efficacy of 
PSs in our trial was not diminished by the components of rye bread. We can 
therefore conclude that rye bread is a suitable food carrier for PSs, and at the 
same time PS enrichment can further potentiate the beneficial health effects of 
whole-grain rye bread. Ultimately, combining the results from the dietary 
intervention (Studies III and IV), whole-grain rye bread enriched with PSs can 
provide dietary protection against CVD, being able to both reduce LDL-C and 
improve the in vitro oxidation resistance of these lipoprotein particles. 
 
4) Plasma DHBA in overnight fasting blood samples served as a suitable 
biomarker for rye bread intake (study compliance) in our dietary intervention. 
Plasma DHPPA could also be utilized, but here DHBA showed higher 
concentrations and responded more clearly to none vs. moderate vs. high 
intakes of rye bread than did DHPPA. 
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